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INTRODUCTION 
Liver transplantation has undergone tremendous advances over 
the past 27 years and has become the accepted treatment for end-
stage liver disease and fulminant hepatic failure. Its current 
success can be attributed to international collaborative efforts 
to achieve: 
1) development of animal models for laboratory investigation 
of liver disease and liver transplantation 
2) understanding of the pathophysiology and natural history 
of liver disease 
3) identification of pathologic criteria of liver disease 
4) establishment of multi-organ procurement and preservation 
techniques 
5) standardization of surgical techniques 
6) developments in anesthetic management 
7) establishment of safe and efficacious immunosuppressive 
regimens 
8) advances in critical care medicine 
9) recognition of post-operative complications 
The first report of experimental orthotopic liver 
transplantation was by Dr. Jack Cannon of the University of 
California, Los Angeles, in 1956.' Subsequent experimental efforts 
in the laboratory resulted in sufficient progress for initiation 
of human orthotopic liver transplant ion in 1963. Seven such 
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transplants were performed without success until 1967 when the 
first longterm survival was achieved in Denver, Colorado. 2,3 
In the early years, liver transplantation developed in two 
directions: auxiliary and orthotopic liver transplantation. 
Although a number of auxiliary liver transplantations were 
attempted, almost all failed. However, auxiliary liver 
transplantation contributed to our knowledge of hepatic physiology, 
including the importance of splanchnic venous flow in the 
maintenance of the grafted liver. 4,5 Although Dr. Joseph Fortner 
reported the first longterm survivor of auxiliary liver 
transplantation performed at the New York Memorial Hospital in 
1972,6 this represented an exceptional case. Thus, auxiliary 
liver transplantation was abandoned in favor of orthotopic liver 
transplantation. More recently there has been a renewed interest 
in auxiliary transplantation for selected indications. 
Prior to 1980, the results of liver transplantation were poor. 
Although the reasons for this were multifactorial, an important 
factor was the lack of safe and effective immunosuppressive 
regimens. The mainstay of anti-rejection therapy included 
azathioprine, steroids and anti-lymphocyte globulin (Table I). The 
rates of rejection and infection were high with various regimens 
employing these agents. Clearly, a better form of 
immunosuppression was required before liver transplantation could 
enter its next stage of development. 
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In 1979, Sir Roy CaIne demonstrated the efficacy of a new 
immunosuppressive agent, cyclosporine A, in 34 patients receiving 
36 cadaveric organ allografts? However, the true potential of 
cyclosporine was only recognized when cyclosporine was combined 
wi th prednisone by Starzl and colleagues. Regimens employing 
cyclosporine allowed a better balance between prevention of 
rejection and minimizing the liability of infection in the 
immunosuppressed patient. Better control of rejection and a more 
manageable post operative course facilitated the rapid progress in 
the field of liver transplantation. The number of liver 
transplantations performed each year since 1981 increased 
tremendously, as did the number of new transplantation centers 
throughout the united States and the world (Table II). 
Immunosuppression entered a new level of sophistication with 
the introduction of monoclonal antibodies specific for T-
lymphocytes for the treatment of severe rejection. One such agent, 
OKT3, has successfully reversed unremitting rejection in many 
patients concurrently treated with steroids and cyclosporine, 
thereby averting retransplantation and even death. 
Technical advances have also contributed to the increasing 
success of liver transplantation. One of the most important 
advances was the introduction, in 1983, of heparin-free veno-venous 
bypass. 8 The use of veno-venous bypass during the anhepatic phase 
has facilitated the maintenance of a stable hemodynamic state 
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during completion of the recipient hepatectomy and implantation of 
the new allograft. It has allowed the most critical part of the 
transplantation procedure to be performed in a calm and safe 
atmosphere thereby allowing the training of new transplantation 
surgeons, so important in the world wide dissemination of this 
procedure. Other technical advances have included standardization 
of the biliary 
transplantation, 
tract reconstruction, 
new applications of 
segmental 
auxiliary 
liver 
liver 
transplantation, liver transplantation in continuity with other 
abdominal organs and advances of the procedure in the very small 
pediatric patient. In addition, employment of vascular allografts 
has allowed transplantation to be performed in patients with portal 
vein thrombosis as well as inadequate hepatic arterial flow. 
Liver transplantation is a multidisciplinary effort which has 
required advances in all fields of medicine. The technical growth 
has been paralleled by advances in anesthesiology, critical care, 
hepatology, radiology, blood banking, as well as most other medical 
specialties. 
The standardization of the techniques of organ retrieval and 
the ability to procure multiple organs from a single donor have 
also been essential for the growth of liver transplantation. 
Furthermore, recent introduction of the new preservation solution, 
the university of Wisconsin Solution, has extended liver allograft 
preservation to 24 hours. 9 This has allowed more organs to be 
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retrieved from greater distances and has contributed to an 
increased donor pool. 
Liver transplantation has contributed to the understanding of 
normal hepatic physiology as well as to the pathophysiology of 
liver disease. Through the correction of specific inborn errors 
of metabolism, the genetics and molecula.r biology of many of these 
diseases have been defined. Through the study of the effects of 
the disease process on the new allograft, hepatology has been 
advanced. However, the most important contribution of liver 
transplantation is its ability to cure many hepatic diseases for 
which there had been no alternative treatment. Patients with liver 
failure have been restored to health and returned to a normal, 
active, and good quality of life. 
INDICATIONS 
As the field of liver transplantation progressed from an 
experimental procedure to standard therapy, its indications 
markedly expanded. Early on, liver transplantation was 
predominantly offered to patients with unresectable hepatic 
malignancies, patients in fulminant hepatic failure, or patients 
who were so critically ill and debilitated from their hepatic 
failure that liver transplantation was the only alternative to 
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imminent death. In such patients, the outcome and survival rates 
were poor. 
As the field progressed to its present state, the indications 
for liver transplantation expanded to include a large variety of 
liver diseases (Table III). The survival and quality of life 
resulting from liver transplantation for most of these indications 
is excellent, however, some indications are still evolving. 
Adult 
The three most common indications in adults include 
postnecrotic cirrhosis, primary biliary cirrhosis, and sclerosing 
cholangitis. The decision regarding the timing of transplantation 
for patients with these indications can often be difficult. 
Ideally, the patient should undergo transplantation at such time 
when morbidity and mortality would be minimized yet it is apparent 
that the patient's long term survival is jeopardized by the liver 
disease. Al though much is known about the natural history of these 
diseases, there is no sUbstitute for early referral and close 
monitoring for subtle signs of deterioration. 
Hepatic malignancy has become a much less common indicaton for 
transplantation, the major reason being the poor long term 
survival. In most cases, there is an early recurrence of the 
malignancy with rapid progression to death. This has led to a 
closer look at the various types of malignancies for which 
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transplantation has been performed. For certain pathologic types 
there is a better prognosis than for others. Those malignancies 
with a better outcome include the fibrolamellar variant of 
hepatocellular carcinoma, epithelioid hemangioendothelioma and the 
coincidental tumor found at the time of transplantation for chronic 
liver failure. There have also been occasional long term survivors 
found with other types of malignancies including hepatocellular 
carcinoma. 10 
The reduced survival after transplantation for most hepatic 
malignancies compared to non-malignant diseases has led to 
variations in policy among different centers. Very careful 
evaluation is required preoperatively to determine the exact extent 
of the disease. In some centers this includes an exploratory 
laparotomy and lymph node sampling prior to consideration of 
transplantation. Various ancillary treatment modalities are being 
explored and it would appear that the future of transplantation for 
malignancies must include combinations of perioperative and 
adjuvant chemotherapy. 
Cholangiocarcinoma has been found to rapidly recur following 
orthotopic liver transplantation. 1o New and much more aggressive 
methods of surgical treatment for this disease are being explored. 
Recently, a new approach employing an upper abdominal exenteration, 
the so called cluster procedure, with replacement of a liver or 
liver and pancreatic graft has been employed. 11 The results for 
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this procedure are preliminary and long term follow-up will be 
required to determine the efficacy of this approach. 
Another important indication for which institutional policies 
ha.ve varied is for the patient with cirrhosis secondary to 
infection with hepatitis-B virus. The one and five year survival 
rates for patients who are surface antigen positive have been 
uniformly inferior to that of other liver diseases. 12 Recurrence 
is the rule. However, the natural history following 
transplantation spans a spectrum from fulminant hepatitis to 
recurrent bouts of hepatitis with spontaneous resolution to 
recurrent cirrhosis requiring retransplantation. There are, 
however, a large number of long term survivors and, accordingly, 
attention is being focused on the peri operative management of these 
patients. Various protocols have been employed to prevent 
recurrence including the use of interferon, hyperimmune hepatitis 
B immunoglobulin and monoclonal antibodies against hepatitis B 
surface antigen. Prevention of allograft infection and management 
of patients with recurrence will remain important topics of future 
research. 
Another controversial indication is alcoholic cirrhosis. The 
determination of candidacy relies heavily on the psychosocial 
evaluation. Cardiovascular evaluation to assess cardiomyopathy is 
also an important focus of the evaluation procedure. Although the 
accompanying physical and psychiatric stigmata of patients with 
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alcoholic cirrhosis were once believed to result in poor outcome, 
it has been shown that success is common with proper patient 
selection. Indeed, recent results for transplantation of alcholic 
cirrhosis have been as good as for other adult disease 
indications. 13 
Transplantation is the therapy of choice for acute and 
subacute fulminant hepatic failure due to a variety of etiologies. 
This is the most dramatic of all indications for transplantation. 
The decision to undertake transplantation must be made rapidly as 
these patients can progress rapidly to grade 4 coma, at which point 
transplantation may have a poor outcome. 14 The decision is 
facilitated when there is evidence of rapid progression of 
encephalopathy and/or coagulopathy, as well as hemodynamic 
instability. Once it becomes clear that spontaneous recovery is 
unlikely, transplantation should be undertaken rapidly to prevent 
a poor neurologic outcome or death. 
Through modification of genetic disease processes, 
transplantation has provided benefits to patients and increased 
understanding of hepatic physiology. Transplantation has been 
performed for the purpose of treating liver failure, as well as for 
the correction of a single metabolic error in selected diseases. 
Metabolic diseases which have been cured by liver transplantation 
include Wilson's disease, Tyrosinemia, Alpha-1-Antitrypsin 
deficiency, galactosemia, Crigler-Naj j ar type I, 
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hyperlipoproteinemia types II and IV, protoporphyria, sea-blue 
histiocyte syndrome, and several glycogen storage diseases. 
Equally striking is the correction of a number of coagulation 
defects following liver transplantation. 
Pediatric 
The medical indications for adult and pediatric liver 
transplantation are comparable. Any child with end-stage liver 
disease should be considered as a potential candidate for liver 
transplantation. Transplantation is indicated for life-threatening 
bleeding, recurrent episodes of encephalopathy, coagulopathy, 
malnutrition, severe jaundice, profound growth retardation or 
metabolic bone disease. When it is clear that survival greater 
than one year is unlikely, considerations for evaluation and 
candidacy for transplantation should be initiated. This is 
particularly important for small children for whom donor organ 
availability may be limited. Accurate assessment of the individual 
child's probability of survival may be difficult or impossible. 
If liver function is stable, specific therapy (i.e., sclerosis of 
esophageal varices, diuretics, fluid restriction, salt restriction, 
etc.) may be more appropriate. However, if liver function is 
progressively deteriorating, then transplantation therapy is 
indicated. The possibility of future transplantation must be 
considered whenever interventions are discussed. Any intervention 
which may jeopardize suitability for transplantation should be 
carefully contemplated. For example, a failed portacaval shunt 
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with thrombosis of the portal system may make liver transplantation 
technically impossible. 
Numerous hepatic diseases in children have been successfully 
treated with liver transplantation. In all series, extrahepatic 
biliary atresia remains the most frequent pediatric diagnosis 
requiring transplantation. 15-19 controversy surrounds the utility 
and the role of the Kasai portoenterostomy in the treatment of this 
disorder. In a significant percentage of individuals (25-30%), if 
surgery is performed within the first two months of life, biliary 
drainage and successful outcome may be achieved. However, multiple 
attempts at revisions to establish bile flow, peritonitis, and 
intraabdominal hemorrhage all contribute to technically more 
difficult surgery and a reduced likelihood of success if 
transplantation becomes necessary. Therefore, an attempt to 
establish bile flow before two months of age in children with 
extrahepatic biliary atresia should be made by surgeons experienced 
in the Kasai procedure. If bile drainage is not established, 
evaluation for liver transplantation should quickly ensue. Even 
if bile drainage is incomplete, the Kasai procedure may facilitate 
improved survival by allowing the child to grow thus increasing the 
availability of suitable donor organs. 
Disorders in the formation and development of the biliary 
ductal system comprise the majority of the pediatric patients who 
undergo orthotopic liver transplantation. While extrahepatic 
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biliary atresia represents the most common indication, Alagille's 
syndrome (arteriohepatic 
nonsyndromatic intrahepatic 
included in this category. 20 
dysplasia) , Bylers 
biliary hypoplasia 
disease, 
entities 
and 
are 
The next largest category requiring liver transplantation in 
pediatric patients consists of genetic disorders of metabolism. 21 -
23 The more common inborn errors of metabolism requiring liver 
transplantation include alpha-I-antitrypsin deficiency, Wilson's 
disease, tyrosinemia, glycogen storage disease, and galactosemia. 
Rarer metabolic disorders for which hepatic transplantation has 
been utilized include Crigler-Najjar syndrome type I, 
hyperlipoproteinemia types II and IV, protoporphyria, and the sea 
blue histiocyte syndromeK~D~ 
Alpha-I-antitrypsin deficiency is inherited as an autosomal 
recessive disorder with a frequency of 1 in 2,000 individuals. 
While not all homozygous individuals develop liver disease, of 
those who develop liver disease, the majority will demonstrate 
cholestasis during infancy. Most of these infants will 
subsequently become anicteric, but the stigmata of significant 
liver disease will eventually ensue, usually during adolescence or 
early adulthood. 
Liver transplantation corrects the enzyme deficiency with the 
recipient acquiring the protease inhibitor type of the donor. 
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Serum alpha-I-antitrypsin levels quickly return to the normal range 
after transplantation. 21 Long-term follow-up of children 
transplanted for alpha-I-antitrypsin deficiency has failed to 
disclose any evidence for pulmonary or other organ disease. 
Evaluation for liver transplantation should proceed in any 
individual with the diagnosis of alpha-I-antitrypsin deficiency who 
manifests any signs of significant liver disease or demonstrates 
decompensation. While infusion of alpha-I-antitrypsin to adults 
with pulmonary complications of the disorder has been useful, this 
approach is not beneficial for hepatic complications of the 
disorder. Since patients with mild liver disease at presentation 
may decompensate rapidly, careful observation and prompt referral 
for transplantation should be considered if jaundice or mild 
coagulopathy develop. 
Wilson's disease remains one of the few hepatic disorders in 
which early diagnosis can lead to effective medical therapy 
employing d-penicillamine or trientine therapy in conjunction with 
dietary copper restriction. Transplantation should be reserved for 
those patients with Wilson's disease who present with fulminant 
hepatic failure or failure of medical therapy. Transplantation 
cures the disordered copper metabolism. Transplantation should be 
undertaken prior to the development of significant neurologic 
deterioration, although reversal of severe neurologic deficits has 
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been observed following transplantation in Wilson's disease 
patients. 
Hereditary tyrosinemia is an autosomal recessive disorder with 
a frequency of one in 100,000 births. The disease may present 
either acutely in the first weeks of life with fulminant hepatic 
failure, or after six months of life with cirrhosis, renal tubular 
defects, rickets and failure to thrive. Onset disease after 6 
month of age has been associated with the development of hepatoma. 
Serum tyrosine and methionine levels are markedly elevated and 
succinylacetone is present in the urine. Transplantation results 
in normalization of serum tyrosine levels and prevention of 
hepatoma development; however, the effect on the status of 
metabolic derangements in other organs is not well characterized. 
Glycogen storage diseases have been successfully treated by 
orthotopic liver transplantation. 25 Long-term follow-up has 
demonstrated normalization of glucose homeostasis. 
While in adults posthepatic cirrhosis is the most common 
indication for liver transplantation, in the pediatric group this 
is a much less common indication. Infants in this group may 
include those with the diagnosis of neonatal hepatitis, hepatitis 
B and non-A, non-B hepatitis. Any child in this group who 
demonstrates life-threatening complications of the liver disease, 
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retarded growth or development, or poor quality of life should be 
evaluated for liver transplantation. 16-18 
Acute fulminant hepatic failure signifies another group of 
pediatric patients who may undergo hepatic transplantation. 26 This 
may be the result of a toxin-induced hepatic failure, a viral 
hepatitis, or a metabolic disorder (Wilson's disease, tyrosinemia) • 
Frequently, the etiologic agent remains unidentified. Development 
of hepatic encephalopathy in conjunction with coagulopathy is an 
immediate indication for referral to a transplant center. Previous 
reports of poor results in patients with fulminant hepatic failure 
may be the consequence of waiting too long and attempting 
transplantation in individuals in deep coma. 
Hepatic transplantation has also been utilized in the therapy 
of unresectable hepatic malignancies in children. 27 The primary 
tumor type has been hepatoblastoma. As in adults, survival rates 
have not been encouraging and the future approach will include the 
use of peri-, intra- and post-operative chemotherapy. 
Numerous other disorders in children associated with liver 
failure have been treated utilizing hepatic transplantation. For 
example, hemochromatosis, cystic fibrosis, sclerosing cholangitis, 
drug-induced cirrhosis, autoimmune hepatitis, and Budd-Chairi 
syndrome may all occur in pediatric patients and necessitate a 
transplant evaluation and procedure. 16-19 The indications and 
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contra indications for these patients are similar to those already 
discussed. Of course, each patient requires an individual 
assessment as circumstances will vary for each. 
EVALUATION 
The evaluation process is directed towards the determination 
of the need and urgency for the performance of an orthotopic liver 
transplant as well as the feasibility of performing this procedure. 
The need and urgency are determined by obtaining a careful 
history, performing a physical examination and obtaining various 
laboratory data as well as reviewing any biopsies which may have 
been obtained in the past. The feasibility determination requires 
evaluation of the entire medical status of the patient including 
the cardiovascular, pulmonary and renal systems. Furthermore, the 
use of various radiologic techniques permits definition of the 
vascular anatomy and size of the liver that are required for liver 
transplantation. 
As with approaching any medical disease, a careful history 
must first be obtained. Specific areas to be defined include: 
possible etiologies of the liver disease, prior complications 
secondary to liver disease, previous surgical procedures and the 
current disability of the patient. Liver disease resulting from 
17 
prior alcohol or IV drug abuse will require further evaluation. 
A psychiatric and sociologic evaluation should be performed to 
ascertain the patient's determination to abstain from further 
substance abuse, as well as the patient's ability to comply with 
the postoperative medication regimen and medical follow-up. 
The specific areas of concern regarding complications of the 
liver disease include episodes of encephalopathy, ascites, edema, 
gastrointestinal bleeding, infections (particularly spontaneous 
bacterial peritonitis), and inability to perform one's daily 
routine. Prior complications in conjunction with ongoing hepatic 
disease, demonstrated by decreased synthetic function, are clearly 
indications for liver transplantation. The urgency must be 
determined based on the severity of the complications as well as 
the presence of current disabilities. 
Necessary laboratory data include a complete blood count, with 
special attention to signs of hypersplenism, and chemistries to 
define the electrolyte status and liver function. Elevated 
bilirubin levels indicates impaired hepatic excretory function 
while an elevated protime and decreased serum albumin demonstrate 
impaired hepatic synthetic function. Hepatitis serologic tests are 
obtained to identify those patients who are hepatitis-B surface 
antigen positive as these patients will require concurrent medical 
treatment in addition to liver transplantation. A CEA and an 
alpha-fetoprotein are obtained and, should either one be elevated, 
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a search for occult malignancy or hepatocellular carcinoma must be 
undertaken. The CEA is especially important in those patients with 
sclerosing cholangitis as a 10% incidence of a concomitant 
cholangiocarcinoma has been reportedK~ A 24 hour urine collection 
for creatinine clearance is obtained to define the presence and 
degree of renal dysfunction, which may require adjustments in the 
dosage of postoperative immunosuppressive medications. 
various bacterial, viral and fungal cultures and titers are 
obtained to establish a baseline for each patient as well as to 
identify those infectious disease processes which may 
require treatment prior to transplantation. A tuberculin skin test 
is performed with an appropriate control panel. 
HIV antibody test is obtained. 
In addition, an 
Additional laboratory examinations, aimed at the determination 
of the etiology of the liver disease, are tailored for each 
individual patient. These include antimitochondrial antibody, 
anti-nuclear antibody, anti-smooth muscle antibody, ceruloplasmin, 
urine copper, alpha-1-antitrypsin level and phenotype, and drug 
screen. 
Cardiopulmonary evaluation is individualized for each patient. 
An arterial blood gas and chest x-ray are routinely obtained. 
Should there be an indication, such as hypoxemia, history of 
extensive smoking and/or prior pulmonary disease, pulmonary 
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function tests are also performed. An EKG is routinely obtained 
and once again should there be an indication, a cardiac stress 
test, 2-D echocardiogram and/or coronary angiogram may be required. 
The radiologic evaluation is primarily directed towards the 
elucidation of the technical feasibility of transplantation as well 
as the collection of data which will be required for suitable 
donor-recipient matching. Doppler ultrasonography is performed to 
determine the patency of the hepatic veins, hepatic artery and 
particularly the portal vein as well as the presence of biliary 
tract disease. Should portal vein patency be in question, an 
angiogram must be performed to define the portal system anatomy. 
Although previously thought to be a contraindication to orthotopic 
liver transplantation, portal vein thrombosis is now no longer an 
absolute contraindication. The presence of an adequate superior 
mesenteric vein, however, is required for the performance of the 
procedure. 
A CT scan of the head and abdomen are performed. The presence 
of intracranial lesions must be determined prior to undertaking the 
transplantation procedure as the presence of any vascular anomaly 
may lead to catastrophic events intraoperatively. Furthermore, the 
presence of encephalopathy requires the exclusion of other causes 
of altered mental status. The CT scan of the abdomen will 
demonstrate any intra- or extrahepatic malignancies and provide the 
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liver volume which is so important in the donor-recipient 
matching. 29 
We are finding an increasing value in the use of magnetic 
resonance imaging in the evaluation process. This procedure 
provides us with similar data as the CT scan of the abdomen and 
demonstrates the presence of flow in the portal vein. with further 
studies confirming the reliability of this modality, MRI may become 
the primary radiologic test in the evaluation of these patients. 
Patients with sclerosing cholangitis are scheduled for 
percutaneous transhepatic cholangiography and brush biopsies. As 
previously stated, there is a 10% coincidence of 
cholangiocarcinoma. Due to the dismal results of orthotopic liver 
transplantation for patients with a biliary tract malignancy, it 
is important to evaluate its presence prior to transplantation. 
In the presence of cholangiocarcinoma new alternative treatment 
methods, such as the cluster procedure, may prove to be of value. 
Endoscopic evaluation of the upper gastrointestinal track is 
performed to determine the presence of and potentially treat 
esophageal varices. Colonoscopy is performed in patients over 40 
years. 
Once the evaluation process is completed, the final 
determination for the need and urgency for transplantation is made 
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by a multidisciplinary institutional selection committee. 
Transplantation is indicated in the presence of end-stage liver 
disease manifested by: encephalopathy, ascites, impaired renal 
function, gastrointestinal bleeding, inability to perform one's 
daily routine, and decreased hepatic synthetic function. In the 
presence of these factors, a determination of feasibility is 
rendered. Currently, the contraindications for orthotopic liver 
transplantation are: 
1) presence of active infection exclusive of the 
hepatobiliary system 
2) acquired immune deficiency syndrome 
3) technical impossibility 
4) multiorgan system failure which is irreversible 
by orthotopic liver transplantation 
5) irreversible brain damage 
6) inability to comply with the postoperative 
medication and medical follow up regime. 
The evaluation and selection process for orthotopic liver 
transplantation has undergone maj or extensions to include aged 
patients, small infants, critically ill patients, and patients with 
portal vein thrombosis. 
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There are currently no age limits set for patients to be 
considered for transplantation. The oldest patient to have 
received an orthotopic liver transplant is a 76 year old women with 
primary biliary cirrhosis. Well selected patients over 60 years 
of age have been shown to have a survival rate similar to that of 
younger patients. 30 
Improvements in the technical aspects of the transplant 
procedure have made it feasible to transplant very small infants. 
The youngest patient to have received a liver is a three week old 
infant. Children under the age of one can now be successfully 
transplanted with a good survival rate. 31 
Advances in critical care medicine, anesthesiology as well as 
other medical specialties have made it possible to maintain and 
transplant critically ill patients. Although patients who are 
ventilator dependent, require pressors, dialysis or are in coma 
preoperatively constitute a high risk population, many of these 
patients can be salvaged through transplantation and can go on to 
enjoy long-term survival with excellent quality of life. 
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PREOPERATIVE MANAGEMENT 
The increased success of orthotopic liver transplantation has 
led to expansion of its indications and efforts to optimize timing 
for transplantation. The concept that an optimal time exists for 
transplantation, after which patients suffer increased morbidity 
or mortality, has now been validated. 32 Clinical and laboratory 
factors correlated with the success of transplantation have been 
codified into a risk stratification scoring system. Risk factors 
include degree of encephalopathy, presence of ascites, degree of 
malnutrition, serum bilirubin, age, requirement for transfusion 
during transplantation and degree of coagulopathy. A prospective 
analysis from the University of Nebraska showed that patients with 
a low risk score had an actuarial survival of 90.5% for one year. 
Patients with intermediate and high risk scores had significantly 
diminished actuarial survivals of 85.2% and 44.5%, respectively. 
Although these results indicate that patients should be 
transplanted prior to the development of a high risk profile, many 
patients continue to be referred late in the course of their 
illness and require meticulous management in the preoperative phase 
to countermand the adverse impact of the complications of terminal 
liver disease prior to transplantation. Table IV lists the most 
significant management problems encountered in this preoperative 
population. 
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Hepatic Encephalopathy 
The degree of portal systemic encephalopathy at the time of 
transplantation is inversely related with survival. stratification 
of 115 adult patients with chronic liver disease transplanted 
between 1985 and 1988 at the University of Nebraska showed 
actuarial survival rates of 89.6% in the absence of preoperative 
encephalopathy. The actuarial survival rate diminished to 78.6% 
in patients with mild encephalopathy (stages I-III), and 33.6% in 
patients with severe encephalopathy (stages III-IV). 
The initial approach to management requires evaluation of 
reversible factors that may have precipitated or intensified 
encephalopathy. These factors include: infection and fever, 
hypokalemia, metabolic alkalosis, gastrointestinal bleeding, 
sedatives or narcotic analgesics, and constipation. Once 
precipitating factors are identified, specific measures should be 
taken to alleviate them. After treatment of precipitating factors, 
patients with stage I and II encephalopathy should receive 
lactulose orally in a dose sufficient to produce two to three semi-
soft bowel movements per day.33 For patients with stage III or IV 
encephalopathy, lactulose should be administered if intestinal 
peristalsis is present. Endotracheal intubation is required to 
protect the airway from possible reflux and aspiration pneumonia 
in patients with stage III-IV encephalopathy. Oral or nasogastric 
administration of neomycin may also be utilized. However, the 
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long-term use of neomycin should be avoided because of the chronic 
sequella of mid-range hearing loss. 
Although reports indicate that the administration of branch 
chain amino acids may be of benefit in the treatment of chronic 
portal systemic encephalopathy,34 studies evaluating this modality 
in patients awaiting transplant have not been reported. Similarly, 
studies using flumazenil to antagonize the GABA-benzodiazepine 
receptor complex have been reported in only a few patients with 
fulminant hepatic failure prior to transplant. 35 Since these 
therapies do not improve hepatic function, they should have minimal 
impact on prognosis following transplantation. 
Infection 
Localized and systemic bacterial infections are common 
complications of end-stage liver diseases in adults. Such patients 
are immunocompromised, both by their liver disease and the commonly 
accompanying state of malnutrition. Typical signs and symptoms, 
as well as laboratory tests indicative of infection, may be subtle 
or absent. Thus, the clinician must be alert to the possibility 
of infection and prepared to treat promptly with minimal 
provocation. 
Bacterial peritonitis 
Recurrent bacterial peri toni tis may develop either insidiously 
or with evidence of fever, sudden hepatic decompensation or onset 
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or worsening of hepatic encephalopathy.36 Abdominal findings of 
tenderness and rebound are infrequently present. Peripheral 
leukocytosis may also be absent, especially if a patient is 
leukopenic on the basis of hypersplenism. The clinical diagnosis 
is made by a diagnostic paracentesis in which ~ 250 mononuclear 
cells/rnrn3 are present. 37 Although a variety of antimicrobial 
regimens have been advocated, a recent randomized controlled trial 
indicated a superiority for treatment with a third generation 
cephalosporin. 38 Subsequent adjustments in coverage can be made 
on the basis of culture and sensitivity results. In addition, 
single antibiotic coverage prevents potential nephrotoxicity 
associated with aminoglycosides. 
Response to therapy can be moni tored by subsequent 
paracenteses showing a substantially diminished total white count 
and a decreasing proportion of polymorphonuclear leukocytes. Since 
untreated bacterial peritonitis is an absolute contraindication to 
transplantation, four to five days of antibiotic therapy with 
evidence of a clinical and asci tic fluid response are required 
prior to urgent transplantation. Patients transplanted after this 
abbreviated course should receive antibiotics postoperatively. 
Spontaneous bacterial peritonitis must be distinguished from 
peritonitis secondary to intestinal perforation. since patients 
with cirrhosis have a higher prevalence of peptic ulcer disease and 
may suffer complications associated with stress ulceration, this 
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consideration is mandatory. Diagnostic evaluation, therefore, 
should include an upright PA chest film or decubitus abdominal film 
to identify free intraabdominal air. Features suggestive of 
secondary bacterial peritonitis37 include: 
1) a rising ascites neutrophil count 48 hours after the 
initiation of antibiotic treatment; 
2) positive bacterial cultures from the ascitic fluid; 
3) multiple bacterial organisms; 
4) continued culture positivity despite antibiotic 
therapy; and, 
5) the presence of at least two of three chemical 
findings (ascitic fluid protein greater than 
1 g/dl, glucose less than 50 mg/dl, or lactate 
dehydrogenase greater than the upper limit of 
normal for serum) . 
Further radiologic investigations may be required to identify 
a perforation of the intestinal or biliary tract. 
Ascending cholangitis 
Ascending cholangitis is an infrequent complication in adult 
chronic liver disease, except in patients with sclerosing 
cholangitis, prior biliary tract surgery associated with the 
development of secondary biliary cirrhosis, and internal or 
external biliary prostheses. Clinical signs of cholangitis may be 
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readily apparent with fever, leukocytosis, abdominal pain and 
worsening liver tests. However, the presentation may be more 
insidious. Delay in the treatment of cholangitis predisposes to 
septicemia and hepatic abscesses, which may preclude trans-
plantation. Thus, aggressive empiric antibiotic therapy is 
warranted for suspected cholangitis following appropriate cultures 
of ascitic fluid and blood. In patients with a prior history of 
cholangi tis and several courses of antibiotics, the infecting 
organisms may include gram-positive cocci, gram-negative enteric 
bacilli, enterococci and anaerobic species. Hence, initial 
antibiotic coverage should be broad spectrum. Prophylactic 
regimens of antibiotics for high risk patients following the 
resolution of ascending cholangitis may be useful for a limited 
period of time before a donor organ becomes available. 
other infections 
The immunosuppressed nature of end-stage liver disease 
patients renders them susceptible to a variety of other bacterial, 
viral and fungal infections. 39 It may also be associated with the 
reactivation of previously quiescent infections, such as 
mycobacterium tuberculosis or coccidiomycosis. Changes in mental 
status or stages of encephalopathy may also indicate meningitis, 
which must be considered. Bacterial infections of the lung, 
abdominal abscesses and pyelonephritis require a minimum of seven 
to ten days of therapy before transplantation. Viral infections, 
such as herpes simplex types I and II and cytomegalovirus, require 
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antiviral therapy before and after transplantation. Active 
mycobacterial infections require prolonged therapy, while a history 
of untreated infection requires prophylactic treatment. 
Ascites 
Ascites, refractory to medical management, often necessitates 
recurrent hospitalization prior to liver transplantation. Massive 
ascites may be associated with respiratory distress and compromise 
of the cardiovascular hemodynamics. If unrelieved, these situations 
may predispose to atelectasis, pneumonia, and azotemia. Patients 
with tense ascites may be safely managed with a moderate volume 
paracentesis of one to three liters. The role for large volume 
paracentesis40 has not been evaluated in patients awaiting trans-
plantation. However, the potential risks of hypotension and 
azotemia appear unjustified. 
Medical management includes sodium restriction, fluid 
restriction for hyponatremia, and diuretics if renal function is 
normal. Diuretic regimens often include spironolactone or 
amiloride augmented with furosemide or bumetanide. The goal of 
diuretic therapy should be the maximum loss of one-half kilogram 
in weight per day. More aggressive diuresis may cause azotemia or 
precipi tate hepatorenal syndrome. For patients who cannot be 
managed with diuretics, periodic mild to moderate paracentesis 
and/or infusion of salt-poor albumin (75 to 150 g/day) may be used. 
If repeated paracenteses are performed, appropriate chemical 
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studies and leukocyte counts should be ordered with each 
paracentesis to exclude iatrogenic contamination. 
Hyponatremia is the principal electrolyte disturbance 
accompanying refractory ascites and chronic end-stage liver 
disease. 4o Restriction of free water intake is often necessary to 
maintain a serum sodium of greater than 130 mEqjL. Electrolyte 
replacement intravenously may also be required. Severe 
hyponatremia is to be avoided because of its effects on the mental 
status of the patient and its association with central pontine 
myelinolysis. 41 
Renal Insufficiency 
Attention to fluid and electrolyte management, gentle 
diuresis, and avoidance of large volume paracenteses help prevent 
prerenal azotemia. If rising creatinine, however, does occur in 
the face of ongoing diuresis or blood loss, intravascular volume 
should be aggressively replaced and diuretics discontinued. To 
evaluate suspected pre renal azotemia, patients should receive a 
fluid challenge of 500 ml of normal saline intravenously. The 
concentration of urinary sodium should also be measured; the 
expected concentration being S 5 mEqjL. Failure to reverse the 
creatinine elevation or rapidly increasing creatinine are 
indicative of hepatorenal syndrome. Since this syndrome is 
refractory to medical management in the face of deteriorating 
liver function, patients awaiting transplantation with this 
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complication should be maintained on hemodialysis. Typically, 
patients with hepatorenal syndrome recover normal renal function 
within days or weeks following successful liver transplantation. 42 
However, some patients have prolonged postoperative renal 
insufficiency that can often be attributed to prior nephrotoxic 
antibiotics, episodes of hypotension or infusion of radiocontrast 
dyes. A peritoneovenous shunt should not be performed for 
hepatorenal syndrome prior to transplant because of unacceptable 
morbidity. 
Chronic renal failure may also be evident in patients awaiting 
transplantation. Chronic renal failure poses an increased risk for 
early major bacterial infection, and is associated with increased 
mortality in liver transplantation. 43 Patients with chronic renal 
failure should undergo appropriate hemodialysis while awaiting 
transplantation. Selected patients should be evaluated as 
candidates for a combined kidney and liver transplantation 
procedure. 
variceal Bleeding 
Recurrent variceal hemorrhage is common in patients awaiting 
liver transplantation. The frequency of hemorrhage and risks of 
morbidity and mortality increase substantially with worsening 
coagulopathy and thrombocytopenia. The immediate goals of therapy 
are maintenance of intravascular volume with fluids and blood 
transfusion to maintain cardiac output and renal perfusion. 
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Further attempts to stabilize or prevent recurrent bleeding may 
employ intravenous vasopressin, direct tamponade with a Sengstaken-
Blakemore tube, sclerotherapy, or rubber band ligation. 
Uncontrolled bleeding or bleeding from gastric, small bowel or 
colonic varices require urgent transplantation since medical 
therapy is ineffective. The role for sclerotherapy or rubber band 
ligation as prophylaxis for recurrent variceal bleeding for 
inpatients awaiting liver transplantation remains controversial. 44 
studies of beta blocker therapy in patients with end-stage liver 
disease awaiting liver transplantation have not been reported. 45 
Malnutrition 
Malnutri tion in adults undergoing OLT is an adverse prognostic 
indicator of survival. 32 Malnourished patients are particularly 
prone to infection and poor wound healing. Malnutrition is to be 
anticipated in 40-60% of liver patients admitted to hospital. 46 
Often, the malnutrition adds to the immunocompromised state of the 
patients, as evidenced by the high frequency of anergy in 
malnourished patients with end-stage liver disease. Malnutrition 
in end-stage liver disease may be multifactorial. Many patients 
are anorexic or unable to prepare adequate meals. Depending upon 
the type of liver disease, its complications, or necessity for 
hospitalization, excessive caloric expenditures may also be 
present. In patients with chronic cholestatic liver disease, fat 
malabsorption is common and may limit enteral nutritional capacity. 
Reduction in dietary fat to 40 grams per day or use of medium chain 
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triglycerides may be of benefit. Such patients should be 
supplemented with parenteral or water soluble forms of the fat 
soluble vitamins A, D, K, and E. 
The goal of nutritional therapy is to provide adequate 
calories while maintaining appropriate restrictions of total 
protein (for patients with chronic encephalopathy) and sodium (for 
patients with refractory ascites). A full nutritional analysis 
should be made by a dietician. Enteral nutrition is preferable; 
however, peripheral venous or central venous parenteral nutrition 
may be required. 
DONOR SELECTION 
The transplantation process begins with the finding of a 
sui table donor. The criteria for donor selection are variable 
amongst different institutions and are rapidly changing. As liver 
transplantation becomes more universal and new programs become 
established, each program will determine their specific criteria 
for donor acceptance. It is not uncommon for a new program to use 
more stringent criteria for the blood pressure, arterial 
oxygenation, use of pressors, liver function tests, cause of death, 
age, as well as other factors. However, the donor shortage has 
lead to liberalization of these criteria. In more established 
programs where the recipient waiting list may be long, it has been 
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shown that with liberalized criteria, the long-term outcome can be 
equally successful. 47 
The two maj or features which are required for appropriate 
donor-recipient matching are size and blood type; however, even 
these criteria are not absolute. Appropriate size match requires 
the following information: 
1) recipient height and weight 
2) donor height and weight 
3) recipient chest circumference 
4) donor chest circumference 
5) recipient liver volume, calculated via 
radiologic techniques 
6) estimated liver volume of the donor 
By using these figures, an appropriate size match can usually 
be made. One must keep in mind that, depending upon the liver 
disease, the recipient's liver volume may often be much smaller 
than the volume that can be placed in the hepatic fossa. A 
recipient with a small, shrunken liver who has a long history of 
ascites, can certainly take a larger liver than that calculated by 
his own volume. In these instances, it is important to have the 
height, weight and chest circumference of the recipient more 
closely match those of the donor. 
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In the case of the stable candidate, one can usually wait for 
a donor organ of the appropriate size. This becomes more difficult 
when faced with a critically ill patient or a small child. In 
these cases, it may be impossible to find an appropriately sized 
organ prior to further deterioration of the recipient. It is for 
this reason that size criteria has been liberalized to include the 
use of segmental livers which will be discussed later in this text. 
Although transplantation of ABO incompatible kidneys has been 
shown in many cases to result in hyperacute rejection, this has not 
been the case in liver transplantation. Despite the absence of 
hyperacute rejection, the survival for ABO matched grafts still 
remains significantly higher than for ABO incompatible or ABO 
mismatched but compatible grafts. 48 In addition, in the presence 
of an ABO mismatch, a graft vs. host reaction may develop between 
two to three weeks post transplantation. This is manifested by a 
hemolytic anemia which is usually mild and resolves spontaneously. 
However in some cases, this reaction may be severe enough to 
warrant retransplantation. 
Due to the decreased survival rates and the potential for 
graft vs. host reactions, blood type remains an important criteria 
in donor-recipient matching. Once again, this is not an absolute 
criteria and ABO matching may be waived in the face of a severely 
ill patient. 
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Historically, due to the urgency imposed by a short cold 
storage time, donor-recipient crossmatching has not been possible 
in liver transplantation. Retrospective review of donor specific 
crossmatch has, however, revealed no significant effect on graft 
survival. The presence of a positive crossmatch or a high panel 
reactive antibody (PRA) has not been shown to correlate with an 
increased graft loss due to rejection. 48 
HLA matching has also been studied retrospectively and 
histocompatibility has not been shown to increase graft survival. 48 
Clearly, as our ability to preserve grafts for longer periods 
becomes feasible , it will become increasingly important to re-
examine the effects of crossmatching and HLA matching on graft 
survival. 
In the most perfect of circumstances, it would be preferable 
to use organs from only young hemodynamically stable donors with 
normal liver function tests. The shortage of donor organs as well 
as the urgency of transplantation in critically ill patients has 
made this situation impossible. Fortunately, however through the 
use of imperfect donor organs, it has been shown that standard 
criteria for donor selection are not absolute and with some 
relaxation in the criteria, a good longterm outcome can still be 
obtained. 
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Upper age limits are increasing as we find satisfactory 
function obtained from donors greater than 50 years of age with 
otherwise satisfactory criteria. 50 Acceptable arterial blood gases, 
as well as hemodynamic status, vary from institution to 
institution. In the face of a questionable donor, it is always 
preferable to assess the liver intraoperatively. Much can be 
learned by direct examination of the consistency and color of the 
liver. Furthermore, the bile can be inspected at the time of bile 
duct transection. with the availability of the University of 
wisconsin solution, livers can be preserved for 24 hours. This 
allows the procurement team to harvest a questionable liver and 
perform and evaluate a liver biopsy prior to undertaking the 
recipient operation. Through this method, many otherwise wasted 
organs can be salvaged and demonstrate good function. 
Despite liberalization of donor selection criteria, there do 
remain absolute contraindications to the use of an organ. These 
include: 
1) absence of heartbeat 
2) presence of extracerebral malignancy 
3) positive HIV antibody 
4) positive hepatitis antigen status 
5) systemic sepsis 
6) presence of known liver disease 
7) presence of specific toxins 
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Several other variables including liver function tests, fluid 
and electrolyte status, use of pressors and past medical history 
must all be considered in donor selection. 
In the 
institution 
final analysis donor selection 
to institution and will depend 
will vary 
heavily upon 
from 
the 
judgement of the transplantation team. There is currently a search 
for more objective criteria for the prediction of liver function. 
One test which is currently being investigated is the Lignocaine 
Metabolite Formation (MEGX) Test. Preliminary data have 
demonstrated that levels of MEGX following low dose infusion of 
Lignocaine can be used as a predictor of liver function. 51 A closer 
look at this test will be required to determine its reliability. 
Clearly, a search for objective criteria will certainly be in the 
future of liver transplantation. 
SURGICAL ASPECTS 
Donor Hepatectomy 
The first step in the performance of a liver transplantation 
is the procurement of the hepatic allograft. Coordination and 
cooperation are required among the various surgical teams to ensure 
the successful procurement of multiple organs from a single donor. 
Due to significant variations in technique for organ procurement 
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among different transplant centers, the teams should discuss the 
methods and time requirements of the individual procedures prior 
to undertaking the operation, in order to assure optimal 
procurement of each organ with minimal ischemia and injury. 
According to the preservation times which each organ can sustain, 
a priority order has been established for removal of organs once 
the circulation has been arrested. The heart and lungs are removed 
first, followed by the liver, and finally the kidneys. 
A mid-line incision extending from the suprasternal notch to 
the pubic symphysis with good retraction provides sufficient 
exposure and access to the thoracic and abdominal organs. Upon 
entering the abdominal cavity, the different organs are carefully 
inspected to assess suitability for transplantation. This 
comprises evaluation of color, consistency, and size of the various 
organs. The liver is mobilized by dividing the falciform ligament, 
left triangular ligament, and gastrohepatic ligament. When 
dividing the gastrohepatic ligament, it is important to check for 
the presence of a left hepatic artery arising from the left gastric 
artery. A left branch is present in approximately 15 percent of 
donors and if found, must be preserved. The posterior aspect of 
the porta hepatis should also be inspected for the presence of a 
right hepatic artery originating from the superior mesenteric 
artery. Present in approximately 10 percent of the donors, this 
branch can usually but not always be palpatated and, if present, 
must be preserved to assure the viability of the liver. 
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Several techniques have been developed for liver procurement 
and the choice of technique depends upon the preference and 
experience of the recovery team as well as the hemodynamic 
stability of the donor. 52,53 The three techniques currently employed 
consist of: 
1) the classic technique 
2) the standard technique 
3) the rapid-flush technique 
These techniques differ in the amount of dissection, 
especially of the hepatic hilum, prior to circulatory interruption. 
A long preliminary dissection may be time consuming and may require 
blood transfusions. It will, however, require a much less 
difficult and time consuming extraction once the liver is perfused 
and cooled after circulatory arrest. Therefore, this is only 
suitable for a very stable donor. On the other hand, when there 
is less preliminary preparation, more dissection is needed after 
the liver has cooled and this requires a greater degree of skill 
and expertise for safe removal of the liver. 
The three procedures have two common principles: the rapid 
and adequate core cooling of the liver following circulatory 
interruption, and preservation of all hepatic structures, including 
anomalous blood vessels. 
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Classic technique 
This original technique is characterized by a thorough 
dissection of all the hepatic vessels. All the hilar structures, 
including the bile duct, hepatic artery, portal vein, and branches 
of the celiac trunk, are dissected. The left gastric and splenic 
arteries are ligated and divided. The celiac trunk and abdominal 
aorta are dissected. The superior mesenteric artery is identified 
and encircled at its origin. The liver is pre-cooled with cold 
solution through a cannula inserted in the splenic vein. The 
supraceliac aorta is encircled in preparation for cross-clamping. 
The infrahepatic vena cava, as well as the renal veins, are 
isolated. The distal aorta and inferior vena cava are both 
cannulated after full systemic heparinization. Following 
circulatory interruption, the liver is rapidly cooled through the 
cannulae placed in the aorta and the splenic vein. 
cooling, the liver can be removed with a minimum 
dissection. 
standard technique 
Following 
of further 
The standard technique (Figure 1) requires far less dissection 
than the classic technique. The hilum is freed by dividing the 
bile duct, and right gastric and gastroduodenal arteries. The left 
gastric and splenic arteries are ligated and divided distally. 
The portal vein is identified at its confluence and the splenic 
vein prepared for cannulation. The supraceliac aorta is identified 
and prepared for cross-clamping. The distal aorta is dissected and 
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cannulated after systemic heparinization. Following circulatory 
interruption, the supraceliac aorta is cross-clamped and the 
intrathoracic vena cava divided. The liver is then rapidly cooled 
and the hepatectomy is performed. The superior mesenteric artery 
is approached by retracting the distal pancreas and, once 
identified, it is dissected down to the aorta. It is carefully 
inspected for the presence of a right branch and, depending on the 
anatomy, is either included or excluded in the aortic patch 
encompassing the celiac trunk. The infrahepatic vena cava is then 
divided allowing the liver to be removed. 
Rapid flush technique 
This technique requires the least time for preliminary 
dissection and is therefore sui table for unstable donors. The 
inferior mesenteric vein is dissected and cannulated. The distal 
aorta is then dissected and cannulated after heparinization (Figure 
2). The supraceliac aorta is prepared for cross-clamping prior to 
cannUlation of the distal aorta. The remainder of the dissection 
is performed after circulatory interruption and cooling. The 
preparatory steps may take from five to fifteen minutes. However, 
due to the minimal amount of previous dissection, this technique 
demands more skill and experience in the performance of the 
hepatectomy. Following division of the intrathoracic cava and 
cross-clamping of the supraceliac aorta, the liver is rapidly 
cooled and hepatectomy undertaken. The right gastric and 
gastroduodenal arteries are divided to free the hepatic artery and 
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the bile duct is divided. The portal vein is identified at its 
confluence, then the splenic vein and superior mesenteric vein are 
divided to free the portal vein. The left gastric and splenic 
arteries are divided. The superior mesenteric artery is approached 
in the same way as in the standard technique and an appropriate 
patch of aorta encompassing the celiac axis is removed. Once 
again, the infra-hepatic vena cava is divided and the liver removed 
with a cuff of diaphragm. 
The iliac arteries and veins are routinely recovered after 
nephrectomy in the event that venous or arterial grafts will be 
required during the recipient liver procedure. Portions of spleen 
and mesenteric lymph nodes are removed for the purpose of donor-
recipient crossmatching. 
The remaining preparations of the donor liver prior to 
implantation are performed on the backtable at the recipient 
hospital. The liver is carefully prepared by completing the full 
dissection of the hepatic vasculature and performing any hepatic 
arterial reconstruction for anomalies. For livers with anomalous 
left gastric or superior mesenteric arteries, a single common 
arterial channel is created using various techniques in order to 
facilitate anastomosis to the recipient artery. 54,55 
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Recipient operation 
The recipient procedure is comprised of the following stages: 
1) Hepatectomy 
2) Liver implantation 
3) Hemostasis 
4) Bile duct reconstruction 
The completed procedure (Figure 3) consists of four vascular 
anastomoses and one biliary anastomosis. 
Hepatectomy 
The vast majority of liver transplants have been performed in 
an orthotopic position, thus, the first step is the recipient 
hepatectomy. The recipient surgeon must plan the hepatectomy based 
on individual considerations. These considerations include: 
previous upper abdominal surgery, previous episodes of spontaneous 
bacterial peritonitis with resulting adhesions, the nature of the 
liver disease, patency of the portal vein, and the presence of 
portal systemic shunts. 
In order to devascularize the liver, the initial dissection 
is carried out in the hilum. with the exception of malignancies, 
the bile duct and the hepatic artery should be transsected as 
proximal to the liver as possible to facilitate their 
reconstruction. The portal vein is skeletalized and prepared for 
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veno-venous bypass. The remaining liver attachments can be 
divided, before or during veno-venous bypass, depending on the 
presence of coagulopathy and/or diffuse collaterals. A difficult 
hepatectomy can result in significant blood loss, therefore 
achieving hemostasis during the hepatectomy is essential in 
maintaining the stability of the recipient. 
Veno-venous bypass 
During the final stages of the recipient hepatectomy and 
ensuing liver implantation, the recipient portal vein and inferior 
vena cava are cross-clamped, diminishing blood return to the heart. 
Portal vein occlusion results in splanchnic hypertension, 
congestion of the bowel, increased lactate concentrations and 
bleeding in the areas of dissection. Caval occlusion leads to 
renal hypertension, venous stasis and decreased blood return to the 
heart. Since 1982, the use of heparin-free veno-venous bypass has 
significantly improved these problems. 8 Cannulae are inserted into 
the portal vein and inferior vena cava via the femoral vein. An 
atraumatic centrifugal pump channels blood through these cannulae 
back to the heart via a cannula inserted in the axillary vein 
(Figure 4). Veno-venous bypass has facilitated the maintenance of 
recipient stability during this very critical time period. Good 
hemostasis is more readily achieved during the anhepatic phase 
because veno-venous bypass allows the surgeon time to oversew any 
raw surfaces created during the hepatectomy. Use of veno-venous 
bypass reduces postoperative complications, including renal failure 
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and sepsis, and allows a more rapid return of bowel function. 
Veno-venous bypass is now used routinely in most adult and 
pediatric patients weighing over thirty kilograms. 
In some instances, the retrohepatic vena cava can be 
completely preserved. This offers a further advantage in the 
maintanence of blood return to the heart and can be particularly 
useful for small pediatric recipients whose size makes the use of 
bypass practically impossible. Some adult recipients can also 
benefit from preservation of caval flow, i.e. those with portal 
systemic shunts who do not require portal bypass, or in cases of 
significant mismatch in the size of the donor and recipient organs. 
In the presence of severe portal hypertension in the 
retroperitoneum, this technique allows this area to remain intact. 
This is important for older patients and those with cardiac 
instability. In such cases, only suprahepatic vena cava 
anastomosis is performed and the donor infrahepatic cava is 
ligated. This technique has been termed the "piggyback" 
technique. 56 
Graft revascularization 
Anastomosis of the vena cava above and below the liver is 
performed first. While the lower caval anastomosis is being sewn, 
the liver is flushed with cold saline solution to remove the highly 
concentrated potassium contained in the preservation fluid, and air 
from the major veins. Portal bypass is then interrrupted and the 
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portal vein anastomosis is performed. It is extremely important 
to accurately match the lengths of donor and recipient portal 
veins. This will prevent kinking and possible thrombosis. At this 
point, the liver is usually revascularized on portal flow only, 
major bleeding sources are controlled, and the veno-venous bypass 
is terminated. The hepatic arterial anastomosis is then performed, 
preferably by anastomosing the recipient common hepatic artery to 
the donor's celiac trunk, although there are many variations. An 
accurate match between donor and recipient hepatic arteries is 
essential. To prevent twisting and assure an adequate arterial 
blood flow to the liver, the lengths and positions of these 
arteries must be carefully examined prior to anastomosis. 
When the recipient artery is severely diseased, injured, or 
exhibits poor inflow, an alternative source of inflow must be used. 
In most cases an aortohepatic graft is employed. A donor iliac 
graft is anastomosed to the infrarenal aorta, tunneled either 
posteriorly or anteriorly to the pancreas, and anastomosed to the 
donor artery in the hilum. other infrequent alternatives in cases 
where access to the infrarenal aorta is extremely difficult, 
include placement of the graft proximal to the celiac trunk on the 
abdominal aorta, or anastomosis of the donor artery to a common 
orifice fashioned on the main celiac trunk at the takeoff of the 
splenic artery. Various techniques and reconstructions have been 
developed to handle the various hepatic arterial anomalies found 
in the donor liver. Usually performed on the backtable prior to 
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implantation, these reconstructions are meant to produce a single 
orifice for anastomosis. 54,55 
In the past, portal vein thrombosis has been a major 
contraindication to liver transplantation. Depending on the extent 
of thrombosis, different methods of venous grafting have been 
developed and employed with excellent results. 57,58 If the clot 
obstructs only the main portal vein, the donor iliac vein graft is 
anastomosed to the confluence of the splenic and superior 
mesenteric veins. If the extension of the thrombosis includes the 
confluence, a jump graft is placed on the anterior surface of the 
superior mesenteric vein below the transverse mesocolon. This vein 
graft is brought anteriorly to the pancreas through the transverse 
mesocolon and into the hilum. 
Careful collaboration between the surgeon and anesthesiolo-
gist is then required to achieve appropriate hemostasis. This 
includes correction of coagulopathy and careful inspection of all 
surgical sites. 
Bile duct reconstruction 
Standardization of bile duct reconstruction has markedly 
reduced the incidence of postoperative complications, i.e. biliary 
tract leaks and strictures. There are two predominant methods of 
bile duct reconstruction: 59 
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1) choledochocholedochostomy over aT-tube stent 
2) hepaticojejunostomy over an internal stent 
The preferred method is a choledochocholedochostomy over a T-
tube stent (Figure 5a). The simplest of the two techniques, it 
provides an access for easy inspection of the bile and radiologic 
evaluation of the biliary tree. It can only be used in the absence 
of malignancies, bile duct diseases, i.e. sclerosing cholangitis, 
or significant discrepancies in the size of donor and recipient 
ducts. The T-tube is left in for approximately three months after 
the procedure. 
The alternative procedure is a hepaticojejunostomy over an 
internal stent (Figure 5b). A Roux-en-y loop of jejunum is 
fashioned and brought up into the hepatic hilum either anti- or 
retrocolically. This is the anastomosis of choice in pediatric 
cases because of its reliability and extremely low complication 
rate. 
A third alternative, the so-called "Waddell-CaIne" technique, 
uses the gall bladder as an interpositional conduit between donor 
and recipient bile ducts. 60 This technique is rarely used, but can 
be employed when technical difficulties make it impossible to 
fashion a Roux-en-y loop of jejunum. 
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Size Mismatched Donors 
In order to overcome the shortage of small donors in the 
pediatric liver transplant population, surgeons are currently 
exploring technical variations that would allow transplantation of 
grafts procured from size mismatched donors. Such techinques may 
be needed when fulminant hepatitis or graft failure necessitates 
urgent transplantation and no appropriate donor can be found. 
Reduced-size liver technique 
The first such method to be used on a large scale is the 
reduced-size liver technique. 61-63 Reduced-size liver 
transplantation allows a weight ratio of one to six, making 
possible a weight differentiation of 300 to 500 percent between 
donor and recipient. The transplantation of a liver harvested from 
a large donor into a smaller recipient is accomplished by backtable 
resection of the right lobe, either by a bisegmentectomy using the 
left lobe or, more commonly, a trisegmentectomy using the left 
lateral segment. Both procedures require careful backtable 
dissection of the hilar structures and ligation of all of the 
structures transected in the liver parenchyma. Usually the left 
(and occasionally the middle) hepatic vein is preserved in 
continuity with the entire retrohepatic vena cava. The 
implantation is similar to that of an entire hepatic allograft, 
with exact positioning crucial to prevention of vessel torsion 
(Figure 6). In some cases, the recipient's retrohepatic vena cava 
can be preserved and the hepatic segment implanted in "piggyback" 
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fashion (see above). This avoids the need for cross-clamping of 
the vena cava in recipients who are typically too small for veno-
venous bypass. 
split liver technique 
The so-called split liver technique involves the division of 
the liver parenchyme and the partition of vascular and biliary 
structures. This technique addresses the shortage of suitable 
donor livers by allowing two viable grafts to be obtained from a 
single donor for implantation in different recipients. The split-
liver techique continues to evolve with time and with the 
expanding , accumulative experience of transplant teams. 64-66 
Livinq-related donor technique 
without considering, in the present text, the ethical 
implications that have arisen, it is technically feasible to obtain 
a liver segment from a living relative for implantation into a 
pediatric recipient. The living-related transplant procedure has 
been successfully performed in numerous cases. 67 The technique for 
donor segmentectomy includes hilar dissection, parenchymal 
transection, and isolation of the hepatic vein included with those 
segments. Once the vessels to this segment have been clamped, the 
hepatectomy is performed, and the organ is flushed and cooled on 
the backtable. 
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Auxiliary liver transplantation 
Until recently, the technique of auxiliary liver trans-
plantation was abandoned in favor of orthotopic transplantation. 
However, a few high-risk patients have recently undergone auxiliary 
transplantation with reports of some successK~ In auxiliary liver 
transplantation, a segment of donor liver is implanted beneath the 
recipient's liver, which remains in place (Figure 7). The 
usefulness of the procedure requires further evaluation and, in the 
future, may be considered under very special circumstances. 
POST OPERATIVE CARE 
Graft Function 
For purposes of postoperative evaluation, hepatic function 
can be divided convienently into three general categories: 
synthetic, excretory and metabolic. Synthetic function includes 
the production of coaguation factors, albumin and other proteins 
such as transferrin and haptoglobin. Excretory function includes 
the excretion of bilirubin as well as the detoxification and 
excretion of drugs. Metabolic function includes glucose and lactate 
metabolism (including glycogenolysis and gluconeogenesis) and the 
intermediary metabolism of fat and protein. When evaluating the 
postoperative function of a hepatic allograft it is important to 
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note that specific functions of the liver recover from cold 
preservation at different rates. 
synthetic Function 
Immediate hepatic synthesis of coagulation factors is necesary 
for hemostasis and successful completion of the transplant 
operation. with the addition of coagulation factors, in addition 
to the factors produced by the newly implanted liver, hemostasis 
can be attained. In the operating room, thromboelastography is 
used to assess to the status of the interaction of platelets and 
coagulation factors. 69 In the post-operative period, platelet 
count, prothrombin time and partial thromboplastin time are usually 
sufficient to monitor the coagulation status. The prothrombin 
time, which reflects ongoing synthesis of specific factors by 
hepatocytes, is an early indicator of graft function. Although 
normalization is a encouraging sign, occasional prolongation occurs 
despite good graft function as a result of vitamin K deficiency. 
with the exception of vitamin K administration, aggressive 
correction of coagulation abnormalities with exogenous factors in 
the early post-operative period should be avoided so that graft 
function can be monitored by changes in the prothrombin time. 
Prothrombin times of even 20 to 25 seconds may not require 
treatment with fresh frozen plasma as long as there is no evidence 
of bleeding or serious hypertension. If graft dysfunction requires 
factor supplementation, SUbstantial improvement in prothrombin time 
with infusion of 7-l0cc/kg of fresh frozen plasma indicates the 
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likely recovery of synthetic function with time. If no improvement 
in the prothrombin time occurs, a severe preservation injury or 
technical complication should be suspected and investigated. 
Once the prothrombin time has corrected to within 2 seconds of 
normal, it is no longer a useful guide to graft function. Thus, 
it is unnecessary to measure this parameter daily after the first 
week unless other signs of graft dysfunction are present. 
Activated partial thromboplastin time is rarely abnormal, and 
marked prolongation of APTT suggests the contamination of the 
specimen with heparin. 
Excretory Function 
The production of bile in the operating room is the first 
indication of resumed excretory function. Because of the load of 
hemoglobin that accompanies transfusion during the procedure, 
increases in bilirubin in the first few days after the transplant 
are common, regardless of the function of the graft. Thus 
increases are not indicative of graft dysfuction. Paradoxical 
falls in bilirubin immediately after transplantion can result from 
dilution resulting from blood loss and fluid and blood replacement. 
However, such changes are limited to the first 24 to 48 hours and 
subsequent changes in serum bilirubin are indicative of graft 
function. 
If an end-to-end reconstruction of the biliary system has been 
performed, the bile excreted through the T-tube is an excellent 
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gauge of liver function. The experienced clinician can derive a 
considerable amount of useful information about the graft from 
examination of recently produced bile. Both quality and quantity 
of bile produced are of considerable clinical value. Typically, 
bile is dark golden brown and very viscous and up to 300 cc may be 
produced in per day. As the quantity of bile produced increases, 
the color may become lighter due to the increased content of water. 
Because the amount of bile passing into the gut rather than through 
the T-tube is unknown, a low quantity of bile output may not be a 
serious finding if the bile is of appropriate color and viscosity. 
Light colored or water-clear bile indicate severe graft injury, 
most commonly due to preservation injury, primary nonfunction or 
rejection. 
Another important hepatic excretory function is the 
detoxification and clearance of anesthetic agents as well as 
removal of the toxins of hepatic encephalopathy. Awakening from 
anesthesia is an encouraging sign. To minimize confusion regarding 
the sensorium immediately after transplantation, analgesics are 
administered sparingly, if at all. Fortunately, most patients 
experience a tolerable degree of discomfort during this stage 
without a significant analgesic requirement. Once the patient is 
fully recovered from anesthesia and encephalopathy has cleared, 
narcotics can be given with caution. 
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Metabolic Function 
Metabolic function of the liver is evident immediately post 
implantation. Two parameters which can be followed clinically both 
in the operating room and in the leu are serum lactate 
concentration and temperature. Liver metabolism produces 
significant heat, and rewarming frequently begins shortly after 
unclamping. Inablilty to rewarm or slow rewarming after closure 
of the wound raises concern about poor graft function. similarly, 
the metabolism of lactic acid is an early sign of graft function. 7o 
Generally, serum lactate concentration is normal within 6 to 12 
hours post transplant. Increasing or persistent elevation of 
lactate indicates graft dysfunction. Glucose metabolism is an 
insensitive index of graft function; glucose levels generally 
remain high regardless of graft function. Hypoglycemia occurs only 
in circumstances of severe graft injury. 
Preservation Injury 
Some degree of injury occurs in the preservation of all 
hepatic allografts. Transaminase levels during the first 48 hours 
are generally thought to reflect the degree of preservation injury. 
Interpretation of transaminase levels is not absolute and requires 
consideration of all clinical information. AST levels less than 
2000 and ALT levels less than 1500 suggest moderate preservation 
injury, while levels less than 600 indicate minimal preservation 
injury. with severe preservation injury, additional clinical 
indices of graft dysfunction can be expected. These include 
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decreased clearance of bilirubin, delayed normalization of 
prothrombin time, slowed awakening and persistent encephalopathy. 
In severe cases, lactic acidosis and persistent hypothermia are 
observed. If the AST is over 4000, the survival of the graft is 
questionable. After careful serial evaluation and observation, 
retransplantation may be required. 
Immunosuppression 
Immunosuppression after liver 
continuous monitoring and adjustment. 
transplantation requires 
Although most centers follow 
a standardized immunosuppression protocol, great latitude in 
treatment is required to respond to the needs of individual 
patients. Thus, immunosuppression protocols serve primarily as 
guidelines for the individualized prescription of 
immunosuppression. The need for immunosupression is greatest 
during the first weeks after transplantation when the probability 
of rej ection is the greatest. 71 After 2 to 3 months, the 
immunosuppressive regimen can be moderated as the host immune 
system accomodates to the graft. Cyclosporine and steroids as the 
mainstays of maintenance immunosuppression in most centers. 
The need to provide adequate immunosuppression to prevent 
rejection must be weighed against the increased risk of subsequent 
infections. 72,73 Unfortunately, the adverse effect of 
immunosuppression on host resistance is cumUlative, and the onset 
of infections resulting from over-immunosuppression may 
58 
occasionally be delayed by many months. Alternatively, 
insufficient immunosuppression resulting in rejection may require 
so much additional immuosuppression that the risk of unnecessary 
infectious complications is increased. 
cyclosporine 
The introduction of cyclosporine in 1980 coincided with 
spectacular improvement in the results of liver transplantation. 
The acceptance of liver transplantation as standard therapy for 
end-stage liver disease has accompanied the clinical introduction 
of cyclsporine. 74 ,75 The dominant mechanism of action of 
cyclosporine is the inhibition of mitogen induced production of 
interleukin 2. Additional effects may include reduced production 
of interleukin 1, gamma interferon and interleukin 2 receptor. 
Adverse effects of cyclosporine include renal impairment, 
hepatic dysfunction, hypertension, hyperkalemia, eNS dysfunction, 
hirsutism and gingival hypertrophyK~ 
The dosage of cyclosporine is ordinarily determined by 
measurement of cyclosporine levels in blood or serum. Many assays 
are available, and the desired target levels vary between centers. 
Furthermore, dosage may be limited by toxic effects. 
Unfortunatley, manifestations of cyclosporine toxicity do no 
necessarily indicate achievement of an adequate therapeutic effect. 
Indeed, rejection and cyclosporine toxicity may coexist. 
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steroids 
corticosteroids are the second major component of standard 
immunosuppression in liver transplantation. The action is 
primarily anti-inflamatory although other specific activities have 
been proposed. Generally, high dose steroids are the initial 
treatment and are rapidly tapered during the first 7- 14 days, 
followed by maintenance doses which are slowly tapered during the 
ensuing 3-6 months. 
The usual side-effects of steroid therapy are reduced by this 
initial early pulse and subsequent tapering. Specifically, glucose 
intolerance, catabolism, susceptibility to infection and fat 
accumulation are minimized, although they still remain sUbstantial 
problems when the steroid requirements of individual patients 
remain high. 
Azathioprine 
Azathioprine is frequently used as an 
immunosuppressive agent in liver transplantation. 
additional 
It plays an 
important role in patients who are unable to tolerate adequate 
doses of cyclosporine due to side effects, primarily renal failure 
or CNS disturbances. At sub-therapeutic doses it facilitates 
reduction of cyclosporine dosage while minimizing the adverse 
effects associated with full therapeutic doses of azathioprine. 
60 
The mechanism of azathioprine is 
particularly on rapidly dividing cells. 
primarily cytotoxic, 
Thus, proliferating, 
activated immune cells are susceptible to its action. 
Granulocytopenia, and occasionally thrombocytopenia, manifestations 
of toxicity, may require reduction of the dose. The dose may be 
reduced further when hypersplenism results in leukopenia or 
thrombocytopenia. Because of its relatively non-specific mode of 
action, the dose of azathioprine is generally reduced or the drug 
discontinued when infection is present. There is also concern 
regarding long-term hepatotoxic effects and predisposition to 
lymphoproliferative disorders. 
Rejection 
While the aim of maintenance immunosuppression is to prevent 
rejection, this is achieved in only about 30% of liver transplant 
recipients. 71 ,77 Once rejection has developed, intensification of 
maintenance immunosuppression is insufficient to reverse the 
process and specific regimens of anti-rejection therapy are 
required. Generally, these regimens consist of high dose steroids 
or specific T-cell cytotoxic therapy. 
virtually all rejection seen early after liver transplantation 
is acute cellular rej ection mediated by the T-cells. Acute 
cellular rejection is rarely seen in the first few days after 
transplantation. Most commonly, the onset of rejection occurs 
between the fourth and fourteenth post operative day. There are 
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few typical symptoms of hepatic rejection. Although fever is not 
uncommon, and patients may report malaise on the first day of 
rejection. These nonspecific signs and symptoms often have 
alternative explanations. Because the organ is free within the 
abdominal cavity, swelling does not usually cause pain as seen with 
renal transplant rejection. 
Antibody mediated hyperacute rejection, more commonly seen in 
kidney transplantation, is extremely uncommon in liver 
transplantation. This is corroborated by the finding that 
cytotoxic cross-matching does not predict outcome in liver 
transplantationK~ Although there are a few reports of hyperacute 
liver rejection, 79,80 it has been speculated that some cases of 
primary graft non-function may also represent hyperacute rejection. 
Vanishing bile duct syndrome'9 may develop at virtually any 
time after transplantion, although it is rare during the first one 
or two months. Characteristically, there is a paucity or 
disappearance of bile ducts associated with non suppurative 
destructive cholangi tis and degenerative changes of bile duct 
epithelial cells attributed to cytokine-mediated injury or 
ischemia. There are several effective therapeutic options for 
acute cellular rejection, but standard regimens are ineffective for 
hyperacute or vanishing bile duct syndrome. 
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The first signs of rejection are elevations of liver function 
tests. IT Bilirubin usually increases, and aminotransferases and 
biliary enzymes may also increase. Fever and malaise as well as 
leukocytosis may also occur. The graft may become enlarged and 
firm on physical examination. Perhaps most important, the bile, 
if available for inspection, will be lighter and less viscous. 
Many centers perform routine biopsy on about the seventh post 
operative day because of the frequency of rejection at this time. 
The typical biopsy findings of rejection are expansion of the 
portal tracts by mononuclear cells , activated lymphocytes and 
frequentlyeosinophils. 81 Polymorphonuclear leukocytes may also be 
present. The critical finding is invasion and damage of the bile 
ducts by the lymphocytes. 82 These findings can be spotty throughout 
the liver and should be noted in multiple portal tracts if the 
diagnosis of rejection is to be confirmed. Cholangitis may exhibit 
similar findings, but the predominance of polymorphonuclear 
leukocytes often provides the correct diagnosis. 
Many laboratory tests have been proposed as aids to the 
diagnosis of rejection, but none has gained widespread acceptance 
or validation. Clinical judgement, standard laboratory tests of 
liver function and liver biopsy remain the standard modalities for 
the diagnosis of rejection. 
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steroid therapy of rejection generally consists of a brief 
course of very high doses of intravenous corticosteroids for 1-3 
. . t . d 1971 77 days or a bolus followed by taperlng doses of cortlcos erOl s. . . 
A response is often seen within several hours of bolus injection. 
If there is no response to the steroid therapy or if rebound 
rejection should occur after the steroid therapy, OKT3, a murine 
monoclonal antibody against T cells may be given daily for 7 to 14 
days. This drug binds to the CD3 component of the CD3-T cell 
receptor complex present on all mature T cells and causes T cell 
inactivation which interrupts the rejection process. 83 other 
antibody preparations that act similarly by binding to T cells 
include antilymphocyte, antilymphoblast and antithymocyte 
antibodies. 
Once rejection is controlled, maintenance immunosuppression 
is often intensified for several weeks or months to prevent 
recurrence. This may take the form of additional steroids or the 
conversion from dual drug (cyclosporine and steroids) to triple 
drug (addition of azathioprine) therapy. In some cases, rejection 
cannot be controlled by maximuim therapy and retransplantation is 
required. Although the result of retransplantation for rejection 
is not as good as with the initial transplant, rejection does not 
necessarily recur. M 
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Renal Function, Fluid, and Electrolytes 
There is a close relationship between liver and kidney 
function, and many patients with end-stage liver disease have 
significant renal impairment. In the setting of impaired renal 
function, the insult of operation, sUbstantial blood loss, 
temporary occlusion of the vena cava and large doses of intravenous 
cyclosporine results in some renal injury in the majority of liver 
transplant recipients. Fortunately, this injury is usually 
transient and dialysis is rarely needed. Oliguria is a common 
finding in the first two post operative days and requires 
aggressive fluid administrationd guided by pulmonary artery 
pressure monitoring and hemodynamic evaluation. Once adequate 
volume expansion is achieved, as indicated by a pulmonary capillary 
wedge pressure of 14 to 17 torr, large doses of loop diruetics are 
indicated if urinary output does not improve. Typically, the BUN 
and creatinine will rise for 48 to 72 hours regardless of urinary 
output. The first sign of recovery from the perioperative renal 
injury is a decline in creatinine. The BUN usually rises for 
another 24 to 48 hours before declining. Severe cyclosporine 
toxici ty may sustain the elevated BUN despi te improvement of 
creatinine and urine flow. As discussed below , post-operative 
bleeding may further impair urine output and cause oliguric acute 
renal failure in extreme instances. 
Preoperative hepato-renal syndrome has prompted some centers 
to advocate simultaneou.s liver and kidney transplantation. Others 
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have expected the prompt return of renal function with restoration 
of hepatic function and have deferred kidney transplantation for 
those who fail to respond to liver replacement alone. 85 In those 
patients with pre-existing renal failure, hepatorenal syndrome or 
perioperative renal failure, the timing of dialysis after liver 
transplantation is critical. It is wise to delay hemodialysis for 
as long as possible in order to avoid anticoagulation, platelet 
destruction and subsequent bleeding. continuous arterio-venous 
hemofiltration or veno-venous hemofiltration can provide 
alternatives to hemodialysis for fluid removal as well as a very 
mild dialysis with minimal anticoagulation in the perioperative 
period. This is particularly useful in cases of severe volume 
overload or hemodynamic instability and can achieve significant 
volume losses over a period of several days. 
positive intraoperative fluid balance is expected during liver 
transplantation and a gain of 10% or more of the preoperative 
weight is not unusual even after significant losses of asci tic 
fluid. If subtantial blood loss is encountered, weight gain of up 
to 20% may be anticipated. Most or all of this volume is 
sequestered in the interstitial space and in the "third space." 
Much of this fluid can be mobilized and excreted in the third to 
fifth post-operative days if renal function is adequate. Removal 
of this fluid usually requires the use of diuretics even in the 
absence of renal injury. The addition of albumin to the diuretic 
regimen may increase the response if the serum albumin is low. As 
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mentioned above, ultrafiltration is an option for fluid removal if 
the renal function is poor but hemodialysis is otherwise not 
needed. If interstitial fluid is not removed as it is mobilized 
into the vascular space, pulmonary edema may ensue. Careful 
management of volume status with central pressure monitoring may 
be necessary to manage difficult cases. 
The common use of diuretic therapy in the first week after 
transplant often causes electrolyte imbalance with hypokalemia, 
hypomagnesemia and alkalosis. Metabolic alkalosis may result from 
many causes. 86,87 The transfusion of large volumes of blood products 
supplies sUbstantial amounts of citrate which are converted by the 
liver to bicarbonate for several days after transplantation. 
Acidosis during the hepatectomy and the anhepatic phase may occur 
because of accumulation of lactate and require infusion of sodium 
bicarbonate. Once the liver is reperfused and lactate metabolism 
is restored, the residual bicarbonate may also contribute to post-
operative alkalosis. Naso-gastric suction further aggravates 
alkalosis because of the loss of chloride, as does diuretic therapy 
which results in losses of potassium and chloride. The ensuing 
alkalosis may be quite severe and stimulate compensatory 
respiratory acidosis. This may result in small tidal volumes and, 
theoretically, may contribute to atelectasis. systemic alkalosis 
also alters oxyhemoglobin dissociation and impairs oxygen 
availability to the tissue, a potentially serious problem if 
arterial oxygenation is poor or tissue perfusion is impaired. This 
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could theoretically contribute to further damage of grafts 
compromised by severe preservation injury. 
Treatment of alkalosis usually begins with aggressive 
replacement of potassium deficits with potassium chloride. At the 
same time, ventilation is adjusted to normalize pH and optimize 
oxygen delivery. Severe alkalosis constitutes a relative 
contraindication to extubation because of the risk of compensatory 
respiratory acidosis, hypoventilation and atelectasis. Some 
patients maintain normal PAC02 despite severe alkalosis rather than 
compensating with hypoventilation. In this case there is no 
contraindication to extubation in the face of metabolic alkalosis. 
If hypoventilation delays extubation, may result in atelectasis or 
impaired tissue oxygenation, or if alkalosis results in pH above 
7.5, treatment with intravenous hydrochloric acid is appropriate. 
Risks associated with infusion of concentrated hydrochloric acid 
include hemolysis and tissue injury resulting from extravasation. 
Carbonic anhydrase inhibitors are generally inadequate and may 
alkalinize the urine and enhance reabsorption of ammonia from the 
urine, potentially aggravating encephalopathy. Ammonium chloride 
is contraindicated to minimize the ammonia load requiring 
conversion to urea by the newly implanted liver. 
Potassium deficits are common with the aggressive use of loop 
diuretics to maintain urine flow and achieve negative fluid 
balance. Because of the risk of oliguria or anuria during the early 
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postoperative period, replacement has usually been given by 
intermittent infusions of potassium chloride. Addition of 
potassium to the maintenance fluid has traditionally been avoided 
because of potentially severe hyperkalemia that might result from 
sudden graft failure and concommi ttant renal failure. This 
complication is now rarely seen, and addition of potassium to the 
maintenance fluid is probably safe if urine flow is adequate. 
Maintenance of magnesium concentrations is particularly 
important because of the correlation between seizures during the 
early postoperative period of cyclosporine infusion and low or low-
normal magnesium levels. Prior to aggressive replacement of 
magnesium deficits, postoperative seizures were common while 
patients were receiving intravenous cyclosporine. Once the magnesum 
levels were regularly maintained at 2 meqJdl or more, seizures 
became quite rare. 
Cardiovascular 
Cardiovascular complications of liver transplantation are 
fortunately quite 
been considered 
rare. significant cardiovascular disease has 
a compelling contraindication to liver 
transplantation. with improvement in anesthesia, post operative 
management and relaxation of formerly rigid age limits, patients 
with preexisting cardiovascular disease have more commonly become 
liver transplant candidates. Relatively mild degrees of cardiac 
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impairment are acceptable among candidates, and satisfactory 
results have been obtained. 
Pulmonary artery catheterization, thermodilution cardiac 
output and intra-arterial monitoring have become standard practice 
in liver transplantation. Cardiac function is easily evaluated in 
the intensive care unit using standard techniques in those patients 
with preexisting cardiac dysfunction or complications resulting 
from perioperative events. The effect of liver failure on altered 
hemodynamics must be appreciated. One should be aware of the 
reduction in afterload. Typically, cardiac output is high, 
resistance is low, ej ection fraction is supranormal and mixed 
venous saturation is high. These changes are the result of marked 
peripheral shunting. After liver transplantation, the shunts 
persist for a considerable period of time before resolving. The 
rapidity of this change is uncertain since hemodynamic monitoring 
is ordinarilly withdrawn within the first few days after 
transplantation and the hyperdynamic state persists beyond this 
time. 
pulmonary 
Pulmonary function is of paramount importance in the first few 
postoperative days. Pulmonary complications are frequent, but with 
careful management they are infrequently serious. 88 In contrast, 
minor respiratory complications, if not managed aggressively, can 
result in death. 
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The typical postoperative patient returns to the intensive 
care unit intubated and requires several hours to several days of 
mechanical ventilation. The awakening process is delayed compared 
to other maj or surgical procedures, probably because of slow 
hepatic metabolism of anesthetic agents and muscle relaxants and 
residual hepatic encephalopathy. Accordingly, prolonged awakening 
results in a sUbstantial period during which the patient would be 
at risk for aspiration unless intubated. 
All patients have impaired pulmonary mechanics resulting from 
the extensive upper abdominal incision which transects abdominal 
oblique muscles on the right as well as both rectus muscles. Many 
will have concommitant muscle atrophy resulting from malnutrition 
and prolonged hepatic failure. Finally, right, left or bilateral 
phrenic nerve injury occasionally results from clamp placement or 
hemostatic sutures in the diaphragm. 
Renal dysfunction, common in the first week after 
transplantation, often requires aggressive volume expansion which 
may contribute to pulmonary compromise because of volume overload 
with decreased pulmonary compliance, alveolar collapse and 
increased respiratory effort. 
Premature extubation of debilitated or encephalopathic 
patients may result in respiratory failure due to atelectasis or 
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aspiration pneumonia. Careful evaluation of mental status, chest 
roentgenogram and pulmonary mechanics prior to withdrawal of 
mechanical ventilatory support and airway protection can minimize 
these complications. Once pulmonary mechanics are adequate, the 
patient is evaluated for the ability to voluntarily cough and deep 
breathe. A simple, standardized test of cognitive function is 
performed to assess residual encephalopathy or persistent effects 
of anesthesia. If all criteria are satisfied, the patient can be 
confidently weaned and extubated. This practice rarely prolongs 
by more than a few hours the period of intubation and permits 
detection of those patients at highest risk for aspiration, 
atelectasis and pneumonia following premature extubation. 
Right pleural effusion is a routine finding after liver 
transplantation. 89 Left-sided effusions are less common but not 
unusual. Effusions are transudative and may attain considerable 
volumes. If the volume of effusion impairs pulmonary mechanics or 
contributes to atelectasis, therapy is indicated. Although 
diuresis may reduce the volume of the effusion, thoracentesis 
provides a more rapid effect. Such drainage often allows earlier 
weaning and extubation, thus reducing the risk of nosocomial 
pneumonia. 
Atelectasis is also a common postoperative pulmonary 
complication. The incidence of basilar atelectasis is probably no 
more common after liver transplantation than after other major 
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upper abdominal procedures and resolves with mobilization of the 
patient and close attention to pulmonary toilet. Lobar or whole 
lung collapse is infrequent but requires aggressive management. 
Turning, bagging and suctioning are important in prevention and 
treatment of atelectasis and may be sufficient treatment for minor 
collapse. More extensive collapse may result from major airway 
complications including malposition of the endotracheal tube, large 
mucous plugs and blood clots. Such problems may be evaluated at 
the bedside and by portable chest roentgenogram and can frequently 
be treated appropriately without delay. positive pressure 
maneuvers can rapidly reinflate collapsed lung once obstruction is 
relieved. If pulmonary lavage, suctioning and bagging with 
positive pressure do not promptly inflate the lung, prompt 
bronchoscopy is necessary. 
Pneumonia is currently an infrequent complication of liver 
transplantation if the above precautions are observed. Pneumonia 
is most frequently bacterial in origin during the first two weeks. 
Subsequently, protozoal, fungal and viral pneumonias are more 
common, with cytomegalovirus and pneumocystis seen most frequently. 
with improvement in anesthetic management and a more stable 
intraoperative course, adult respiratory distress syndrome (ARDS) 
has also become an infrequent complication of liver 
transplantation. Treatment of ARDS resulting from liver 
transplantation is no different from the treatment of ARDS 
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resulting from other causes. However, the adverse effects of PEEP 
on hepatic blood flow must be appreciated when treating ARDS. This 
may be particularly important when preservation injury or rejection 
produces edema of the graft and further reduction in blood flow 
resulting from PEEP may exacerbate graft ischemia. 9o 
Late pulmonary complications are most commonly infectious and, 
as mentioned, cytomegalovirus and pneumocystis are the most 
frequent organisms. 91 Adequate prophylaxis with sulfamethoxazole-
trimethoprim or pentamidine has virtually eliminated pneumocystis 
pneumonia. CMV remains a substantial problem but progress in the 
prevention and treatment of CMV has substantially reduced the 
clinical impact of this organism. Both CMV and pneumocystis can 
present with a frank pneumonia, but more commonly the initial signs 
are subtle and may consist of isolated fever, mild dyspnea or 
tachypnea. Hypoxemia on room air has been a useful early sign of 
opportunistic infection and should prompt thorough evaluation of 
possible pulmonary infection. Broncho-alveolar lavage provides the 
diagnosis most consistently with minimal morbidity, and open lung 
biopsy is now rarely necessary. other possible etiologies for 
pneumonia should also be considered including tuberculosis, 
legionella and fungi. with aggressive and appropriate early 
detection and management, severe pulmonary compromise and 
intubation and mechanical ventilation are usually unnecessary. 
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Infection and Prophylaxis 
Broad spectrum antibacterial prophylaxis is given 
intravenously prior to operation and for 2 to 5 days afterward. 
There has been a trend to shorten the duration of perioperative 
antibacterial therapy in an effort to minimize the selection of 
resistant organisms. The addition of oral antibacterial and 
antifungal therapy may decrease the colonization of the gut by 
yeast and opportunistic gram negative organisms. 92 Patients 
recieving lactulose preoperatively, those undergoing prolonged 
operations (greater than 12 hours), those undergoing second 
operations and those cared for in the intensive care unit for more 
than 24-48 hours prior to transplant have also recieved short 
courses of low dose amphotericin B in an effort to reduce 
colonization and minimize fungal infections. 
Pneumocysitis carinii pneumonia has virtually disappeared with 
the introduction of low dose trimethoprim-sulfamethoxazole therapy 
for 3 to 6 months after transplantation. 93 For those allergic to 
sulfa drugs, inhaled pentamidine is advocated. 94 The prevention of 
cytomegalovirus infections has been less successful, al though 
acylovir has proven to be an effective prophylactic agent. 95 
Intravenous human IgG has also shown promise in the prevention of 
CMV infections. 96 Finally, gancyclovir, a potent treatment for 
established CMV infections has markedly reduced morbidity and 
mortal i ty. 97 
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Surgical complications 
Bleeding 
As noted earlier, initial graft function must be adequate for 
completion of the procedure with satisfactory hemostasis. The 
abdomen is not usually closed until the surgical team is satisfied 
that the entire surgical site is dry. Postoperative bleeding is 
most often the result of poor surgical hemostasis unless the graft 
is severely injured. Some blood loss from the surgical site is 
acceptable, but ordinarily drainage from the abdomen consists 
primarily of ascites and the hematocrit of such drainage is usually 
less than 5%. Intrabdominal drains are not infallible indicators 
of bleeding and a significant hematoma may develop without 
excessive drainage. Computerized tomography may identify a large 
hematoma when clinical findings are equivocal. 
significant bleeding is frequently associated with oliguria 
and, if the urine output is poor, the need for more than 1 or 2 
units of transfusion in the first 12 hours is cause for concern. 
If significant bleeding occurs, reoperation is often required to 
evacuate the blood clot even though active bleeding is infrequently 
observed at operation. 
Hepatic Artery Thrombosis 
The parenchymal tissue of the liver is capable of surviving 
on portal blood flow alone, making the early clinical detection of 
thrombosis of the hepatic artery difficult. In addition, the 
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infrequent nature of hepatic artery thrombosis makes detection all 
the more challenging. Routine doppler ultrasound can be used as 
a screening test for hepatic arterial flow. 98 The test is very 
sensitive for detection of reduced or absent flow, but relatively 
non-specific. Thus, if the sonographer is unable to demonstrate 
arterial flow, a confirmatory angiogram is necessary before 
corrective therapy is undertaken. If detected early, reoperation 
may restore flow and prevent the need for retransplantation. 
Alternatively, if flow is demonstrated, one can be confident of 
hepatic artery patency. 
Several syndromes have been associated with untreated 
thrombosis of the hepatic artery. 99 The earl iest, and least common 
occurs in those rare grafts which depend on arterial flow for 
survival. In such grafts, hepatic artery thrombosis produces a 
sudden graft failure with severe coagulopathy, renal failure, 
hyperkalemia, encephalopathy and hypoglycemia. Urgent replacement 
of the graft is necessary if the patient is to survive. The other 
three syndromes result from dependency of the bile duct on hepatic 
artery blood flow. If the arterial thrombosis occurs early, the 
bile duct anastamosis fails to heal and leakage develops. Should 
the artery thrombose later, multiple ischemic intrahepatic bile 
duct strictures may develop. Finally, intrahepatic bile ducts may 
undergo ischemic necrosis with formation of multiple bile lakes or 
abcesses. Most of these complications are irreversible and require 
retransplantation. While waiting for a donor organ, abcesses or 
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cholangitis should be treated by appropriate drainage and 
antibiotics. 
Bile Duct Complications 
The blood supply of the common bile duct is quite tenuous and 
may explain the tendency of bilary anastamoses to scar and 
stricture when immunosuppression is withheld. 100 steroids and other 
immunosuppressive drugs prevent biliary sclerosis wich may explain 
the relatively low incidence of biliary stricture in the transplant 
population. Biliary tract leaks usually result in signs and 
symptoms of an abdominal infection. 101 Diagnosis is usually made 
by cholangiogram. A cholangiogram is simple to perform via a T-
tube or a transjejunal stenti a percutaneous transhepatic 
cholangiogram carries more risk. Leaks of the bile duct 
anastamosis usually require surgery when detected as they rarely 
heal without reconstruction. If such a leak remains undetected 
until an abcess develops, immediate reconstruction is quite 
perilous. Cholangiography is also useful for detection of 
obstruction of the biliary system. Early on, ductal dilation is 
not always present, and a normal sonogram does not exclude biliary 
obstruction. 
Simple strictures may be percutaneously dilated with a balloon 
catheter, although the beneficial effect can be transient. 102 
Conversion of an end-to-end anastamosis to a roux-en-y or 
reconstruction of a roux-en-y provides a more durable result. It 
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is important to note that bile duct strictures can be 
misinterpreted as rejection on percutaneous liver biopsy. The 
presence of increased numbers of polymorphonuclear leukocytes 
around the bile ducts may be the only indications of biliary 
obstruction. When rejection is unresponsive to standard therapy, 
a bile duct complication should be suspected and evaluated. Since 
bile leak or stricture may also result from hepatic artery 
thrombosis, discovery of a bile duct complication warrants an 
investigation of the hepatic artery. 
It is possible for the T-tube or internal stent to occlude the 
bile duct producing chemical abnormalities. This is detected by 
cholangiogram. Removal of the T-tube or percutaneous removal of 
a retained stent can resolve this problem. 101 
Intraabdominal Infection 
Prolonged operation, perforation of the intestine, and 
immunosuppression all increase the risk for intraabdominal 
infection in the liver transplant recipient. Poor nutritional 
status of the candidate preoperatively also increases the risk for 
infection. Bacterial infections are the most common and are most 
frequently associated with biliary complications. 101 These 
infections usually occur during the first few weeks after 
transplantation with fever, leukocytosis or failure to thrive. 
Because of immunosuppression, patients may have minimal signs of 
infection despite large infected abdominal collections. For this 
79 
reason, CT scanning and diagnostic aspiration of intraabdominal 
fluid collections is important in those patients who appear to be 
failing without obvious cause. 
Late intraabdominal infections such as cholangitis and 
intrahepatic abcess are likely to be the result of occult occlusion 
of the hepatic artery or stricture of the bile duct. Diagnosis is 
based on appropriate imaging procedures and cultures obtained at 
the time of drainage. The surgical principle of adequate drainage 
coupled with appropriate antibiotics may be accomplished by 
percutaneous techniques, but open drainage may be neccessary if a 
safe percutaneous route is unavailable or the response to 
percutaneous drainage is not prompt or complete. caution should 
be exercised before routinely draining perihepatic fluid 
colletions, since loculated perihepatic ascites is quite frequent 
and most often benign. Only if infection is clinically suspected 
and other sources of infection have been eliminated, should 
perihepatic fluid collections be aspirated. 
Ascites 
Ascites is almost universal after liver transplantation, even 
if none was present before the operation. This ascites has been 
attributed to open lymphatic vessels in the porta hepatis and the 
surface of the diaphragm. The ascites is usually worse in those 
patients with severe ascites prior to surgery. During the first 
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few days after transplantation, the ascites is ordinarily drained 
by closed suction drainage systems. The amount of fluid which can 
be removed by these systems can be sUbstantial and result in 
significant volume depletion. 
Formation of ascites can increase dramatically when the graft 
is injured by rejection or portal vein thrombosis. A sUbstantial 
increase in ascites should prompt an investigation of possible 
causes of graft dysfunction. Losses of ascites may require 
replacement with an appropriate solution, since fluid removed from 
the abdominal cavity is quite promptly replaced by the formation 
of new ascites at the expense of extracellular fluid and ultimately 
plasma volume. The protein losses associated with ascitic drainage 
can be formidable and some form of replacement either by colloid 
infusions or parenteral nutrition is necessary. 
Occasionally, ascites will persist for more than 4 weeks and 
constitute a demanding patient management challenge with related 
problems of intravascular dehydration and renal failure. In rare 
cases, a permanent peritoneovenous shunt may eliminate the need for 
invasive monitoring and large volume replacements, simplify the 
care of the patient and hasten leu or hospital discharge. 
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Portal Vein Thrombosis 
Portal vein thrombosis is a rare technical complication of 
liver transplantation. 103 If the anastamosis is technically 
adequate, and thrombosis occurs, intrahepatic obstruction of portal 
flow may sometimes be responsible. This may be due to edema 
resulting from severe preservation injury or less commonly, early 
severe cellular rejection. It has been suggested that portal vein 
thrombosis arising in the first few hours after implantation may 
be a manifestation of hyperacute rejection. 
Another possible cause of portal vein thrombosis is clot 
forming within the donor portal system. Such thrombus may form 
wi thin the portal system after a thrombectomy performed upon a 
clotted portal vein during the preparation for hepatic 
implantation. Alternatively, unsuspected pre-existing clot within 
the portal system may be a nidus for thombus propagation within the 
portal system and subsequent portal vein thrombosis. 
Finally, thrombosis due to poor flow in the portal system may 
be the result of high flow portal-systemic shunts arising 
spontaneously or surgically created prior to transplantation. Such 
a situation may be detected if portal vein flow is measured 
intraoperatively, and corrective action taken prior to closure. 
The clinical findings associated with portal vein thrombosis 
are quite characteristic and should rapidly lead to the correct 
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diagnosis after urgent doppler study and confirmatory angiography, 
if necessary. The patient with complete thombosis of the portal 
vein will suddenly become desperately ill, with hypotension, sudden 
and massive ascites, profound hypotension, shock and sepsis. 
Severe coagulopathy, marked elevation of aminotransferases, lactic 
acidosis and hypoglycemia are associated laboratory findings. 
Urgent retransplantation is the only opportunty to salvage the 
patient with portal vein thrombosis and survival for more than 24 
hours is unusual after the diagnosis is made. 
RESULTS 
Liver transplantation has proven to be a successful treatment 
for end stage liver disease since the introduction of cyclosporine 
in the early 1980's. Introduction of this immunosuppressive agent 
was coincidental with other improvements in surgical techniques, 
anesthesiology, critical care medicine and hepatology. Currently, 
the one-year survival rate for all indications is approximately 70-
85 percent. 32,104,105 The five year survival rate, similarly for all 
indications, is 60-70 percent. 104 Survival rates for different 
disease indications, based on the University of Pittsburgh series, 
are outlined in Figure 8. Survival rates for pediatric and adult 
recipients have been similar. The variations noted between centers 
is most likely attributable to differences in patient selection. 
Those centers which have been more aggressive in transplanting 
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patients with difficult anatomical situations and with more 
problematic indications (ie malignancy, hepatitis B), have lower 
survival rates than those centers transplanting carefully selected, 
good risk patients. 
The best survival is achieved for those adult 
transplanted for post-necrotic cirrhosis, primary 
patients 
biliary 
cirrhosis, sclerosing cholangitis without concomitant tumor and 
inborn errors of metabolism. In the pediatric group of patients, 
the best results have been achieved for children transplanted for 
biliary atresia, post-necrotic cirrhosis, and inborn errors of 
metabolism. The indications for which survival is decreased are 
those diseases which can recur after transplantation. These 
include patients with hepatitis B surface antigen positivity and 
hepatic malignancies. Furthermore, patients with acute fulminant 
hepatic failure have shown a decreased survival following liver 
transplantation, most likely due to the advanced state of disease 
and coma with which these patients are often transferred to 
transplant centers. 14 Clearly, early referral for patients with 
acute fulminant failure would improve the outcome and long-term 
survival. 
Those patients transplanted for chronic hepatitis-B who are 
surface antigen positive preoperatively, have, for the most part, 
developed recurrence of their disease following transplantation. 
The one-year survival rate has been reported to be approximately 
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60 percent, 
percent. 106 
and the five-year survival rate, approximately 50 
In comparison, patients transplanted for fulminant 
hepatic failure who are hepatitis B surface antigen positive have 
had 75-80 percent one and five year survival rates. 106 There are 
currently clinical trials underway in various centers exploring 
adjuvant therapy to prevent recurrent disease. These trials have 
included the use of large doses of hepatitis B hyperimmune globulin 
during the anhepatic phase and postoperatively, the use of 
hepatitis-B vaccine in the perioperative period, the use of 
monoclonal antibodies, and the use of interferon. Long term 
follow-up of these patients is required before recommendations can 
be made as to the best perioperative treatment. 
Transplantation for malignant disease has been, for the main 
part, disappointing. In the presence of hepatocellular carcinoma, 
survival has been poor with only occasional long-term survivors. 1o 
For the fibrolamellar variant of hepatoma, survival has been better 
with many patients surviving for prolonged periods despite 
recurrence of the disease. Transplantation, in the face of 
cholangiocarcinoma, has been uniformly disappointing. The cluster 
operation, also termed the upper abdominal exenteration11 , is 
currently being evaluated for this very difficult and frustrating 
indication. Epitheliod hemangioendothelioma has a 90 percent one 
year and 50 percent five year survival rate. 106 
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Although many centers have abandoned transplantation for 
hepatic malignancies, other centers continue to offer 
transplantation to these patients who have no other option for 
cure. However, most centers that continue to transplant patients 
for primary hepatic malignancies have instituted protocols 
employing perioperative chemotherapy to reduce the incidence of 
recurrence. The best survival can be obtained in those patients 
who undergo very careful preoperative assessment to exclude 
extrahepatic disease. This includes extensive radiologic 
evaluation, radionuclear scans, pre-transplantation laparotomy and 
lymph node sampling. 
Patients transplanted for other indications and found to have 
small incidental tumors can attain similar survival rates as 
patients without tumor. 10,106 with improvements in radiologic 
techniques, small intrahepatic tumors can be diagnosed more readily 
than in the past. Therefore, what were previously considered 
incidental tumors may be diagnosed preoperatively. Clearly, it can 
be expected that results for liver transplantation for patients 
diagnosed with tumor will improve in such situations. 
Following liver transplantation, over 80 percent of patients 
return to their normal life-styles. Patients return to school, to 
their family responsibilities, to their employment, and to their 
normal social activities. Despite the use of long-term 
immunosuppressive therapy, many male patients have successfully 
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fathered children, and many females have become pregnant and given 
birth to healthy children. In one report, 20 children were born 
to 17 female patients who had received a wide variety of 
immunosuppressive agents including cyclosporine, imuran, steroids, 
.. d lIt' b d' 107 D . t the polyclonal ant1bod1es, an monoc ona an 1 0 1es. esp1 e 
increased incidence of Caesarian section and premature births, most 
of the children have done well. 
IN THE FUTURE 
Despite the excellent results which have been obtained with 
liver transplantation, the field continues to evolve. Although 
various diseases can be cured with liver transplantation with an 
excellent survival, other diseases will require development of 
efficacious adjuvant therapies before achieving equal survival 
rates. Research is in progress for those diseases which 
demonstrate recurrence following transplantation including 
hepatitis B surface antigen positive cirrhosis and primary liver 
malignancies. A close collaboration between transplantation 
surgeons, hepatologists, virologists and immunologists is required 
to devise perioperative management protocols for patients with 
hepatitis B. A major effort must be directed towards the 
definition of adjuvant therapy to prevent or at least significantly 
alter recurrent disease. 
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The efforts directed towards the management of patients with 
primary hepatic malignancies are multifactorial. The available 
data suggests that better results can be achieved through better 
patient selection, recognition of favorable tumor types, 
modification of the postoperative immunosuppressive regimen, 
administration of adjuvant chemotherapy and the development of new 
operative approaches to these diseases. In the presence of hepatic 
malignancies that cannot be resected by conventional techniques, 
liver transplantation continues as the only hope for cure. Despite 
the occasional longterm survivor, the results for most hepatic 
malignancies remain poor. Carefully conducted trials of 
perioperative chemotherapy will be one area of focus to improve 
this situation. 
Future research must address the supply of sui table and 
adequate donor organs. Improved preservation techniques and the 
development of segmental liver transplantation have alleviated a 
small part of the problem. The feasibility of organ 
transplantation across species has been demonstrated. 108 The 
survival is short, because these allografts succomb to an 
accelerated rej ection process. It is anticipated that with 
improved techniques of immunosuppression and further studies to 
achieve tolerance, xenograft transplantation can become a reality. 
Although frought with ethical and emotional issues, the ability to 
transplant across species would resolve the issue of the organ 
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shortage and would render liver transplantation an elective 
procedure. 
Although cyclosporine helped revolutionize extrarenal organ 
transplantation, rejection and infection remain amongst the most 
common postoperative complications. Efforts are currently underway 
to produce and identify new immunosuppressive agents. Ideally, an 
immunosuppressive agent should be specific for allograft rejection 
while sparing the host from infection. Preliminary data 
demonstrates the effectiveness of a new immunosuppressive agent, 
FK-506, in decreasing rej ection episodes and prolonging graft 
survival. 109,110 FK-506 and cyclosporine appear to have a similar 
mechanism of immunosuppression. However, FK-506 appears to be a 
more potent immunosuppressive agent requiring markedly decreased 
adjuvant immunosuppressive agents. One maj or advantage is the 
ability to wean the recipient from steroids in the early 
postoperative period. Clinical trials are currently underway to 
test and confirm the efficacy and safety of this new drug. 
Over the past 27 years, the field of liver transplantation has 
made great strides. It has progressed from an experimental 
procedure to an accepted therapeutic modality for many patients 
with end-stage liver disease. Survival rates and the quality of 
life have made this the treatment of choice for most patients with 
end-stage liver disease and it can be anticipated that with further 
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developments survival rates as well as quality of life will even 
improve even further. 
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LEGEND 
History of Immunosuppression 
a. Liver Transplantation in the United states 
b. Liver Transplantation in the united Kingdom 
Indications for Orthotopic Liver Transplantation 
Pretransplantation Management Problems 
Procurement of the Hepatic Allograft -
standard Technique 
Common bile duct transected, splenic and 
left gastric arteries ligated, cannula in 
splenic vein for cold perfusion. 
Procurement of the Hepatic Allograft -
Rapid Flush Technique 
Cannulae in inferior mesenteric vein (I.M.v.) 
and aorta beneath the inferior mesenteric 
artery (I.M.a.). 
Completed Liver Transplant Including Four Vascular 
Anastomoses and One Biliary Anastomosis 
IVC = inferior vena cava 
Heparin-Free Veno-Venous Bypass 
Biliary Tract Anastomoses -
a. Choledochocholedochostomy over aT-tube stent 
b. Choledochojejunostomy over an internal stent 
Segmental Liver Transplant 
IVC = inferior vena cava 
HA = hepatic artery 
PA = portal vein anastamosis to confluence 
of superior mesenteric vein and splenic 
vein 
Ao = aorta 
Auxiliary Liver Transplant 
IVC = inferior vena cava 
Ao = aorta 
Survival Rates for Liver Transplantation 
a. Adult 
b. Pediatric 
Adapted from LIVER TRANSPLANTATION A 31-YEAR 
PERSPECTIVE by Thomas E. Starzl, M.D., Ph.D. 
and Anthony J. Demetris, M.D' I a Year Book 
Medical Publishers, Inc. 1990 publication. 
TABLE I 
History of Immunosuppression 
Agent 
Azathioprine . 
Combined Azathioprine-Steroids . 
Polyclonal Antibodies 
Antilymphocyte Globulin 
Cyclophosphamide . . . . 
Immunosuppressive Properties 
of Cyclosporine Identified 
Cyclosporine used in Humans 
Combined Cyclosporine-Steroids . 
Year Reported 
. 1962 
. 1963 
. . . 1966 
. . • 1970 
1972 
1978 
1980 
Monoclonal Antibodies Developed . . . . . . 1981 
Cyclosporine Approved in u.s. . . 1983 
for Liver 
___________________ OL'"""" ......~ .... r ~ ..... 
1983 
1984 
1985 
1986 
1987 
1988 
1989-
Table IIa 
LIVER TRANSPLANTATION IN THE UNITED STATES 
Before 1982 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
Table lIb 
119 
62 
164 
308 
602 
924 
1199 
1680 
LIVER TRAJ.'TSPLANTATION IN THE UNITED KINGDON! 
(est) 
20 
51 
88 
127 
175 
244 
300 
Table III 
INDICATIONS FOR ORTHOTOPIC LIVER TRAl,{SPLAl'ITATION 
I. Chronic Active Hepatitis 
A.Viral 
B. Drug Induced 
C. Autoimmune 
II. Alcoholic Liver Disease 
III. Primary Biliary Cirrhosis 
IV. Sclerosing Cholangitis 
V. Biliary Atresia 
VI. Cholestatic Syndrome 
v1I. Budd-Chiari Syndrome 
VIII. U nresectable 'Hepatic Malignancies 
IX. Fulminant Hepatic Failure 
A.Viral 
B. Drug-Induced 
C. ~fetabolic Liver Disease· 
X. Inborn Errors of lvfetabolism 
A. Wilson's Disease 
B. Alpha-I-antitrypsin Deficiency 
C. Tyrosinemia . 
D. Glycogen Storage Disease Type I 
E. Glycogen Storage Disease Type IV 
F. Hemochromatosis 
G. Homozygous Hyperlipoproteinemia Type II 
H. Crigler-Naijar Syndrome I 
1. Neville's Syndrome 
J. Protein C Deficiency 
K Hemophilia 
L. Urea Cycle Deficiency 
?vi. Cystic Fibrosis 
N. Protoporphyria 
TABLE IV 
PRETRANSPLANTATION MANAGEMENT PROBLEMS 
Hepatic Encephalopathy 
Infection 
Refractory Ascites 
Renal Failure 
Variceal Hemorrhage 
Malnutrition 
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